


Targeting glioblastoma signaling and metabolism with a re-purposed brain-penetrant drug

Graphical abstract



Authors

Junfeng Bi, Atif Khan, Jun Tang, ..., Andrey Rzhetsky, Benjamin F. Cravatt, Paul S. Mischel

Correspondence

jubi@stanford.edu (J.B.), pmischel@stanford.edu (P.S.M.)

In brief

Bi et al. reveal an actionable lipid vulnerability in GBM that can be exploited with a safe, highly brain-penetrant, FDA-approved drug. They show that fluoxetine kills GBMs by blocking acid sphingomyelinase, and they demonstrate that, when added to standard of care, fluoxetine, unlike other SSRIs, significantly improves patient survival.

Highlights

- The unique membrane lipid composition makes GBMs sensitive to SMPD1 inhibition
- Fluoxetine inhibits SMPD1, sphingomyelin metabolism, and EGFR signaling in GBM
- Fluoxetine safely and potently shrinks GBM tumors and prevents recurrence in mice
- Addition of fluoxetine to standard-of-care chemotherapy improves patient survival



Article

Targeting glioblastoma signaling and metabolism with a re-purposed brain-penetrant drug

Junfeng Bi,^{1,2,*} Atif Khan,³ Jun Tang,^{1,2} Aaron M. Armando,⁴ Sihan Wu,^{1,2,5} Wei Zhang,⁶ Ryan C. Gimple,⁷ Alex Reed,⁸ Hui Jing,⁸ Tomoyuki Koga,^{9,10} Ivy Tsz-Lo Wong,^{1,2} Yuchao Gu,¹¹ Shunichiro Miki,⁹ Huijun Yang,^{1,2} Briana Prager,⁷ Ellis J. Curtis,^{1,2,6} Derek A. Wainwright,¹² Frank B. Furnari,^{9,13,14} Jeremy N. Rich,⁷ Timothy F. Cloughesy,¹⁵ Harley I. Kornblum,^{16,17} Oswald Quehenberger,⁴ Andrey Rzhetsky,^{3,18} Benjamin F. Cravatt,⁸ and Paul S. Mischel^{1,2,19,*}

¹Department of Pathology, Stanford University School of Medicine, Stanford, CA, USA

²ChEM-H, Stanford University, Stanford, CA, USA

³Department of Medicine, Institute for Genomics and Systems Biology, University of Chicago, Chicago, IL, USA

⁴Department of Pharmacology, UCSD School of Medicine, La Jolla, CA, USA

⁵Children's Medical Center Research Institute, University of Texas Southwestern Medical Center, Dallas, TX, USA

⁶Department of Medicine, UCSD School of Medicine, La Jolla, CA, USA

⁷Division of Regenerative Medicine, Department of Medicine, University of California San Diego, La Jolla, CA, USA

⁸Department of Chemistry, The Skaggs Institute for Chemical Biology, The Scripps Research Institute, La Jolla, CA, USA

⁹Ludwig Institute for Cancer Research, University of California San Diego, La Jolla, CA, USA

¹⁰Department of Neurosurgery, University of Minnesota, Minneapolis, MN, USA

¹¹Stanford Cancer Institute, Stanford University School of Medicine, Stanford, CA, USA

¹²Department of Neurological Surgery, Northwestern University Feinberg School of Medicine, Chicago, IL, USA

¹³Department of Pathology, UCSD School of Medicine, La Jolla, CA, USA

¹⁴Moore's Cancer Center, UCSD School of Medicine, La Jolla, CA, USA

¹⁵Department of Neurology, David Geffen School of Medicine, University of California Los Angeles, CA, USA

¹⁶Department of Molecular and Medical Pharmacology, David Geffen UCLA School of Medicine, Los Angeles, CA, USA

¹⁷Jonsson Comprehensive Cancer Center, David Geffen UCLA School of Medicine, Los Angeles, CA, USA

¹⁸Department of Human Genetics, Institute for Genomics and Systems Biology, University of Chicago, Chicago, IL, USA

¹⁹Lead contact

*Correspondence: jubi@stanford.edu (J.B.), pmischel@stanford.edu (P.S.M.)

<https://doi.org/10.1016/j.celrep.2021.109957>

SUMMARY

The highly lethal brain cancer glioblastoma (GBM) poses a daunting challenge because the blood-brain barrier renders potentially druggable amplified or mutated oncoproteins relatively inaccessible. Here, we identify sphingomyelin phosphodiesterase 1 (SMPD1), an enzyme that regulates the conversion of sphingomyelin to ceramide, as an actionable drug target in GBM. We show that the highly brain-penetrant antidepressant fluoxetine potently inhibits SMPD1 activity, killing GBMs, through inhibition of epidermal growth factor receptor (EGFR) signaling and via activation of lysosomal stress. Combining fluoxetine with temozolomide, a standard of care for GBM, causes massive increases in GBM cell death and complete tumor regression in mice. Incorporation of real-world evidence from electronic medical records from insurance databases reveals significantly increased survival in GBM patients treated with fluoxetine, which was not seen in patients treated with other selective serotonin reuptake inhibitor (SSRI) antidepressants. These results nominate the repurposing of fluoxetine as a potentially safe and promising therapy for patients with GBM and suggest prospective randomized clinical trials.

INTRODUCTION

The highly lethal brain tumor glioblastoma (GBM) is one of the most difficult forms of cancer to treat. Despite a relatively advanced catalog of the mutational landscape of GBM, genomic insights have failed to translate into improved survival for the vast majority of patients, most of whom still die within 2 years, despite aggressive treatment with surgical resection, radiotherapy, and temozolomide (TMZ) (Cloughesy et al., 2014; Wen et al., 2020). Multiple challenges contribute to persistent therapeutic failure. First, many targeted cancer drugs have relatively poor brain/plasma

ratios, resulting in systemic toxicities that preclude adequate target inhibition in patients. Second, the underlying biology of actionable genetic alterations in the brain appears to be profoundly influenced by the brain's unique physiology in ways that are not well understood (Bi et al., 2020; Brennan et al., 2013; Mack et al., 2016; Nagaraja et al., 2019; Quail and Joyce, 2017). Third, GBMs commonly contain extrachromosomal DNA (ecDNA), in which growth-promoting oncogenes, including the epidermal growth factor receptor (EGFR), are amplified at very high levels (Kim et al., 2020; Morton et al., 2019; Nathanson et al., 2014; Nikolaev et al., 2014; Turner et al., 2017; Xu et al., 2019; Zhou et al.,



2017). Unfortunately, reversible and rapid modulation of the level of these ecDNAs appears to play a key role in driving GBM resistance to targeted therapy (Nathanson et al., 2014), thereby motivating a search for alternative treatment strategies.

The palette of genomic alterations in GBM appears to differ in some consistent ways from that observed in other cancers that do not arise in the brain. For example, EGFR kinase domain mutations, which more commonly occur in other types of systemic cancers, are rare in GBMs (Brennan et al., 2013; Sanchez-Vega et al., 2018), in which instead *EGFR* amplification is a dominant oncogenic mechanism. Under normal physiological conditions, EGFR ligands promote dimerization and downstream signaling (Arhipov et al., 2013; Lemmon et al., 2014). In GBM, the amplified *EGFRs* on ecDNA often contain mutations in the extracellular domain of the receptor, such as EGFRvIII, which disrupt ligand binding but nonetheless promote oncogenic signaling, raising the possibility that something unique about the brain's microenvironment may select for *EGFR* amplifications. This motivated us to consider whether the altered lipid environment in the brain, and potentially in tumor cells, might generate a unique selection pressure in GBMs that may expose actionable vulnerabilities. We focused on lipids because recent work has shown that GBM cells may have profoundly altered compositions of cholesterol and phospholipids in the plasma membrane that may determine how EGFRs signal in tumor cells (Bi et al., 2019, 2020; Guo et al., 2011; Villa et al., 2016). We were particularly motivated to search for alterations in sphingolipid biosynthesis pathways, because the balance between sphingomyelin and ceramide is thought to be critical for plasma membrane organization, including the clustering of signaling molecules into discrete membrane domains called lipid rafts (Hannun and Obeid, 2018; Lingwood and Simons, 2010; Ogretmen, 2018; van Meer et al., 2008). We also searched for highly brain-penetrant drugs that selectively and effectively target key enzymatic components of the sphingolipid biosynthesis machinery.

Here, we proceed from unbiased identification and validation of acid sphingomyelinase (ASM; sphingomyelin phosphodiesterase 1 [SMPD1]) as a compelling GBM target that is required for tumor cell survival to dissection of its underlying actionable enzymatic mechanism to identification of fluoxetine as a US Food and Drug Administration (FDA)-approved, safe, and highly brain-penetrant drug that potently inhibits SMPD1 for the treatment of patients with GBM. We conduct *in vivo* proof-of-concept studies revealing complete tumor regression in patient-derived GBM brain tumor models in mice when fluoxetine is combined with standard of care. Fluoxetine (Prozac) has been prescribed for years (Wong et al., 2005). Therefore, we complement our experimental data with analyses from electronic medical records demonstrating that combining fluoxetine with standard of care, unlike other selective serotonin reuptake inhibitors (SSRIs) analyzed, significantly prolongs survival in patients with GBM.

RESULTS

GBMs highly depend on SMPD1 for survival

Hypothesizing that sphingolipid metabolism may play an important role in glioma pathogenesis (Bi et al., 2020; Noack et al., 2014; Ogretmen, 2018), we analyzed a large-scale RNA interfer-

ence cancer dependency dataset (DepMap) (DepMap, 2020; McFarland et al., 2018) containing over 600 cancer cell lines of different histological types, including 43 glioma cell lines. We focused on 14 genes that encode the key enzymes in the sphingolipid synthesis pathway (Figures 1A and S1A) and are coordinately upregulated in GBM clinical samples (Figures S1B and S1C). We identified SMPD1, also known as ASM, as the top survival dependency among these 14 genes in glioma cell lines (Figures 1B, S1D, and S1E). Concordant with its potential role in driving tumor growth, elevated *SMPD1* expression is associated with significantly shorter survival in patients with GBM from multiple public cancer patient datasets (Figures 1C and S1F–S1H).

Pharmacological inhibition of SMPD1 by fluoxetine selectively kills GBMs

SMPD1 catalyzes the conversion of sphingomyelin to ceramide (Hannun and Obeid, 2018). Complete genetic loss of SMPD1, which occurs in children with Niemann–Pick disease (Schuchman and Desnick, 2017), results in elevated sphingomyelin levels, lysosomal stress, and cell death in some contexts (Hannun and Obeid, 2018; Schuchman and Desnick, 2017). To determine whether GBM cells, because of their enhanced dependence on SMPD1, could potentially be highly sensitive to a pharmacological inhibitor of SMPD1, we searched the literature for FDA-approved, brain-penetrant drugs that have been shown to inhibit SMPD1 enzymatic activity. The SSRI antidepressant fluoxetine was recently identified as a potential SMPD1 inhibitor (Gulbins et al., 2013; Kornhuber et al., 2008). In GBM cells, fluoxetine inhibited SMPD1 enzymatic activity (Figure 1D), resulting in dose-dependent GBM cell death (Figures 1E and S2A–S2D). *SMPD1* overexpression abrogated the effect of fluoxetine on GBM cells, supporting on-target activity (Figures 1E, S2E, and S2F). To further determine the anti-GBM potential of fluoxetine, we performed a sensitivity screen in 3 non-cancer cell lines and 18 patient-derived GBM cultures of various tumor genotypes (Figure 1F; Table S1). Fluoxetine resulted in tumor-specific cell death (Figure 1G) and caused extensive lysosomal stress in the patient-derived GBM cultures (Figure 1H), as would be predicted as a marker for an SMPD1 inhibitor (Schuchman, 2010).

To determine whether the anti-tumor effect could be mediated through the serotonin reuptake system, we analyzed the serotonin transporter SLC6A4 and the serotonin receptor HTR2C. Neither gene was expressed at appreciable levels in GBM clinical samples (Figure 1I), and short hairpin RNA (shRNA) knockdown of either gene did not significantly affect GBM viability, in contrast with shRNA knockdown of *SMPD1*, which caused substantial GBM cell death (Figures 1J and S2G). Other serotonin receptors also failed to show appreciable transcript levels or survival association in the Cancer Genome Atlas (TCGA) GBM dataset (Figures S2H and S2I). Importantly, fluoxetine administration significantly inhibited tumor growth, in accordance with dramatic inhibition of SMPD1 enzymatic activity, in orthotopic xenografts implanted in the brain of nude mice (Figures 1K–1M), which were rescued by *SMPD1* overexpression (Figures 1K–1M). These data do not exclude a potential modulatory role for serotonergic activity in the tumor microenvironment (Caudill et al., 2011; Dolma et al., 2016; Mahé et al., 2004), but they do further suggest that fluoxetine kills GBM cells through an





Figure 1. GBMs depend on SMPD1 for survival, making them sensitive to fluoxetine-mediated cell death

(A) Schematic pathway of sphingolipid metabolism in plasma membrane lipid remodeling of GBM cells.
 (B) shRNA effect scores and mRNA levels of *SMPD1* in glioma and other CCLE cell lines from the DepMap dataset.
 (C) Kaplan-Meier analysis of overall survival of patients with high or low *SMPD1* mRNA expression in the TCGA GBM (RNA sequencing [RNA-seq]) dataset.
 (D) Enzymatic activity of *SMPD1* in U87EGFRvIII cells with 24-h fluoxetine treatment.
 (E) Percentage of Annexin V-positive U87EGFRvIII cells (n = 3).
 (F) Brief information, including major genomic features, of 18 patient-derived GBM neurosphere lines.
 (G) Cell viability curves of three non-cancer cell lines (NHA, RPE1, and IMR90) and 18 GBM neurosphere lines in response to fluoxetine treatment (n = 4).
 (H) LysoTracker staining in indicated cell lines (n = 60).
 (I) mRNA level (RNA Seq V2 RSEM) in TCGA GBM patient samples.
 (J) Percentage of Annexin V-positive U87EGFRvIII cells with indicated shRNA knockdown (non-targeting [NT]).
 (K–M) Representative tumor images (K), *SMPD1* enzymatic activity (L), and tumor signal intensity (n = 7) (M) of U87EGFRvIII orthotopic xenograft models. Scale bar, 5 mm.
 Data represent mean \pm SD, except (I). The median value (center line) and the 25th and 75th percentiles (dashed lines) are presented in (I). Two-tailed Student's t test (B and H). Log rank test (C). ANOVA with Tukey's multiple comparisons test (E, I, J, L, and M). *** $p < 0.001$.
 CN, copy number; n/a, not available; NS, not significant. See also Figures S1 and S2 and Table S1.



(legend on next page)

alternative mechanism, including SMPD1 inhibition *in vitro* and *in vivo*. Together, these results suggest that GBMs depend on SMPD1 for survival and are highly sensitive to fluoxetine-mediated SMPD1 inhibition.

Fluoxetine kills GBM cells by disrupting sphingomyelin metabolism with resultant inhibition of oncogenic EGFR signaling

Many GBMs contain amplified *EGFRvIII*, a constitutively active form mutation of *EGFR* driving GBM malignant progression (Cloughesy et al., 2014). In our sensitivity screen, we found that GBMs with *EGFRvIII* amplification were significantly more sensitive to fluoxetine than other GBMs (Figure 2A). Further, overexpression of *EGFRvIII* in a GBM cell line globally increased sphingolipids levels (Figures S2J and S2K), sensitized tumor cells to an inhibitor of sphingolipid *de novo* synthesis (Figures S2L–S2N), as well as *SMPD1* shRNA knockdown (Figures S2O–S2Q), and generated dose-dependent sensitivity to fluoxetine (Figures S2A–S2C). Patient-derived GBMs with endogenously amplified *EGFRvIII* were similarly highly sensitive to *SMPD1* depletion or fluoxetine, both in neurosphere cultures (Figures 2B–2D and S2R) and in orthotopic xenografts implanted in the brain of nude mice (Figures 1K–1M), further suggesting a potential role of *EGFRvIII* or downstream oncogenic signaling in the anti-GBM effect of fluoxetine.

RNA sequencing in these three *EGFRvIII*-amplified, patient-derived GBM neurosphere lines treated with fluoxetine for 42 h revealed a transcriptional signature indicative of EGFR inhibition (Figures 2E, 2F, and S3A–S3D). Analysis of TCGA GBM clinical samples revealed a highly significant correlation between *EGFR* amplification, the transcriptional signature of EGFR signaling, *EGFR* expression, and *SMPD1* expression (Figures 2G, 2H, S3E, and S3F), suggesting a potential molecular basis for enhanced fluoxetine sensitivity that was consistent with enhanced *SMPD1* survival dependency in glioma cell lines with elevated *EGFR* protein levels. Interestingly, in the merged patient cohort of low-grade glioma and GBM, deep deletion of *SMPD1* and

EGFR amplification/mutations are mutually exclusive ($p < 0.001$) (Figure S3G), suggesting a synthetic lethal interaction between *SMPD1* and *EGFR*. In TCGA clinical dataset, *IDH1* wild-type GBMs with higher *SMPD1* expression have a significantly shorter survival in the *EGFR* amplification/gain cohort and the classical-like cohort (Figures S3H and S3I). We further noted that, surprisingly, in an analysis of the drug sensitivity dataset from DepMap among all 40 glioma cell lines, fluoxetine clustered with 4 bona fide EGFR inhibitors, but not with 4 other SSRI antidepressants (Figure 2I), further indicating the anti-GBM activity of fluoxetine may be through inhibiting EGFR signaling, but not serotonin transporters.

Next, we set out to determine how fluoxetine might affect EGFR signaling. Genetic depletion of *SMPD1* using two independent shRNA constructs suppressed *EGFRvIII* signaling (Figures 2J and S4A). Fluoxetine also potently inhibited *EGFRvIII* signaling, *in vitro* and *in vivo*, which was significantly reversed by overexpressing *SMPD1* (Figures 2K, 2L, and S4B–S4D). Confirming that the loss of *EGFRvIII* signaling contributes to fluoxetine's anti-GBM activity, we focused on AKT, which has been shown as a major signaling output that is required for *EGFRvIII*'s oncogenic effects (Cloughesy et al., 2014). Expression of the constitutively active *AKT E17A-CA* allele significantly rescued the anti-tumor effect of fluoxetine (Figures 2M, S4E, and S4F). Consistent with the significant association between the expression of *SMPD1* with *EGFR*, but not other receptor tyrosine kinases (RTKs) genes, in GBM clinical samples, no obvious change was detected on the activity of PDGFRA, FGFR1, and MET in fluoxetine-treated GBM cells (Figures S3F, S4G, and S4H), suggesting a relative selectivity for EGFR and EGFR-driven signaling as important targets of *SMPD1* inhibition in GBM.

Fluoxetine rapidly inhibited *SMPD1* enzymatic activity (Figure 2N), but inhibition of *EGFRvIII* phosphorylation and downstream signaling became apparent only after approximately 24 h (Figures 2K and S4I), raising the possibility that altered sphingolipid levels may play a key role in suppressing *EGFRvIII* signaling.

Figure 2. Fluoxetine's inhibition of SMPD1 blocks oncogenic EGFR signaling in GBM cells

- (A) Fluoxetine sensitivity (area under the cell viability curve) of 3 non-cancer cell lines and 18 patient-derived GBM neurospheres, including 4 *EGFRvIII*-amplified lines.
- (B) Relative cell viability of *EGFRvIII*-amplified GBM neurosphere lines with *SMPD1* or non-targeting shRNAs ($n = 4$).
- (C) *SMPD1* enzymatic activity in GBM neurospheres with 24 h of fluoxetine treatment ($n = 4$).
- (D) Percentage of Annexin V-positive cells in normal human astrocytes (NHAs) and GBM neurospheres ($n = 4$).
- (E and F) Gene set enrichment analysis identifies differentially enriched or depleted transcripts in three GBM neurosphere cultures treated with fluoxetine versus DMSO.
- (G and H) Gene set enrichment analysis of differentially expressed genes in TCGA GBM clinical samples (HUG133A) with high or low *SMPD1* expression.
- (I) Drug sensitivity correlation of fluoxetine, 4 EGFR inhibitors, and 4 other SSRI antidepressants in 40 glioma cell lines from the DepMap dataset.
- (J) EGFR signaling in indicated GBM cells.
- (K) EGFR signaling in GBM39 cells with 24-h treatments.
- (L) EGFR phosphorylation in U87EGFRvIII orthotopic xenograft tumors.
- (M) Viability of GBM39 cells expressed vector or a constitutively active *AKT E17A-CA* allele ($n = 4$).
- (N) *SMPD1* enzymatic activity in GBM39 cells treated with DMSO or 5 μ M fluoxetine ($n = 4$).
- (O) Schematic of sphingomyelin (d18:1/n16:0-d9) metabolomics assay.
- (P and Q) Abundance of sphingomyelin (d18:1/n16:0-d9) (P) and ceramide (d18:1/n16:0-d9) (Q) in U87EGFRvIII cells with indicated treatment ($n = 4$).
- (R and S) Lipidomics analysis of endogenous sphingomyelins in U87EGFRvIII cells with 24 h of treatment and with *SMPD1* overexpression ($n = 5$). Relative abundance of representative sphingomyelins is plotted in (S).
- (T) LAMP1 staining of GBM cells. Scale bar, 20 μ m.
- Data represent mean \pm SD, except for mean \pm SEM in (S). Two-tailed Pearson (I). Two-tailed Student's *t* test (R). ANOVA with Tukey's multiple comparisons test (A–D, M, N, P, Q, and S). * $p < 0.05$, ** $p < 0.01$, *** $p < 0.001$. See also Figures S2–S4.

To test this hypothesis, we developed a quantitative mass spectrometry assay to determine the effect of fluoxetine on sphingomyelin levels. GBM cells were fed with a deuterated sphingomyelin (d18:1/16:0-d9), which is an SMPD1 substrate. Fluoxetine treatment for 6 h significantly increased the sphingomyelin (d18:1/16:0-d9) level while concomitantly lowering the ceramide (d18:1/16:0-d9) level, which was rescued by *SMPD1* overexpression (Figures 2O–2Q). These results indicate that fluoxetine potentially inhibits SMPD1 enzymatic activity elevating sphingomyelin levels. To confirm these findings and assess the effect of fluoxetine on endogenous sphingomyelins, we performed another mass spectrometry analysis, demonstrating that fluoxetine treatment significantly increased endogenous sphingomyelin levels in GBM cells (Figures 2R, 2S, and S4J–S4L), which was rescued by overexpression of *SMPD1* (Figures 2R and 2S). As anticipated with elevated sphingomyelin, we also observed a lysosomal stress response (Figures 2T, S4M, and S4N).

Disrupting sphingomyelin metabolism inhibits EGFR activity on the plasma membrane of GBM cells

SMPD1 inhibition, by altering sphingomyelin levels, could potentially affect the structural organization of the plasma membrane, including the highly ordered microdomains, referred to as lipid rafts, in which much signal transduction is thought to occur (Arhipov et al., 2013; Bi et al., 2019; Sezgin et al., 2017). Therefore, we analyzed the effect of fluoxetine on membrane order in live GBM cells by using the lipid-phase-sensitive fluorescent probe Laurdan (Owen et al., 2011; Parasassi et al., 1997). Laurdan staining quantifies shifts in the emission spectra generated by probe binding to ordered versus disordered phases in the plasma membrane (Owen et al., 2011). Fluoxetine treatment lowered the generalized polarization (GP) values of the plasma membrane (Figures 3A and 3B). *SMPD1* overexpression reversed the effect of fluoxetine on sphingomyelin profiles and membrane order (Figures 2R, 2S, 3A, and 3B), thereby demonstrating a direct effect on tumor cell plasma membrane architecture. In line with the recent finding that SMPD1 inhibition caused KRAS mislocalization from the plasma membrane (Cho et al., 2015; Schuchman, 2010), fluoxetine treatment resulted in depletion of EGFRvIII from the plasma membrane with loss of downstream EGFRvIII signaling (Figures 3C and 3D), which was rescued by *SMPD1* overexpression, both *in vitro* and *in vivo* (Figures 2L and S4C). Concordant with these changes, we observed a dramatic loss of EGFRvIII from the raft marker-enriched membrane fraction (Figures 3E and 3F) in fluoxetine-treated GBM cells, as well as an enhanced EGFR internalization from the plasma membrane in fluoxetine-treated GBM cells (Figure 3G). This was followed by reduced EGFRvIII protein levels, which was partially rescued by proteasome and lysosome inhibitors (Figures S5A–S5E), potentially explaining the reduced levels of EGFRvIII protein, as well as the reduced levels of pEGFRvIII and its downstream effectors (Figures 2K and S4B).

To further confirm that the effect of fluoxetine on EGFRvIII signaling was mediated by SMPD1 inhibition, we added SM d18:1/n16:0 and SM d18:1/n24:0, the two sphingomyelins that were identified to be highly enriched in GBM (Figure S4L), to GBM cells. Both sphingomyelins significantly suppressed EGFRvIII signaling and GBM cell viability, which was further

enhanced by fluoxetine (Figures 3H and S5F–S5I). Ceramide was not able to rescue these effects (Figure S5F). Further, the addition of SM d18:1/n16:0 caused loss of EGFRvIII from the plasma membrane of GBM cells (Figure 3I), mimicking the effects of fluoxetine. In contrast, blocking sphingomyelin synthase, an enzyme that catalyzes sphingomyelin synthesis from ceramide (Figure S5J), may potentially decrease the sphingomyelin accumulation caused by SMPD1 inhibition. We found that knockdown of *SGMS1*, a key coding gene of the sphingomyelin synthase expressed in GBM and downregulated in *EGFR*-amplified GBMs (Figures S5K and S5L), significantly rescued the cell viability and EGFR activity of GBM cells treated with fluoxetine (Figures S5M–S5P). Taken together, these results suggest that fluoxetine causes loss of EGFR from the plasma membrane and inhibits EGFR signaling by blocking SMPD1 enzymatic activity and elevating sphingomyelin levels (Figure 3J).

Fluoxetine efficacy in patient-derived orthotopic GBM mouse models

Fluoxetine is highly brain penetrant (Bolo et al., 2000; Karson et al., 1993) and is FDA approved for a variety of neuropsychiatric disorders (Eli Lilly and Company, 2017; Wong et al., 2005). It has been demonstrated to be safe over a range of doses from 20 to 80 mg/day, with most depression patients being treated with the lower doses (Eli Lilly and Company, 2017). To better understand how fluoxetine could potentially be used as a treatment, we tested the calculated mouse equivalent oral doses of the FDA-approved dose range in patient-derived, *EGFRvIII*-amplified GBMs implanted into the brains of nude mice (Figures 4A and S6A). In the GBM39 model, we observed significant, dose-dependent tumor growth inhibition and markedly prolonged mouse survival at mouse dose equivalents of 50 and 80 mg/day (Figures 4B, 4C, and S6B). No toxicity was observed (Figure S6C). The low-dose fluoxetine treatment, 4.2 mg/kg, which translates to 20 mg/day in humans, did not affect tumor growth (Figures 4B and 4C). In a second independent, patient-derived, *EGFRvIII*-amplified GBM model implanted into the brains of nude mice, HK296 daily treatment with 10 and 15 mg/kg significantly inhibited GBM growth (Figures 4D and 4E), blocked tumor cell proliferation (Figures 4F and S6D), induced tumor cell death (Figures 4G and S6D), and markedly prolonged mouse survival (Figure 4H), concomitant with EGFR inhibition and increased lysosomal stress (Figures 4I–4K, S6E, and S6F). Importantly, fluoxetine-treated mice showed no evidence of toxicity, no weight loss, and no cell death or elevation of LAMP1 in the surrounding brain, using antibodies that detect both human and mouse protein (Figures 4G and S6C–S6F). These results demonstrate that clinically safe and achievable doses of fluoxetine that can inhibit SMPD1 activity may potentially be used to treat patients with GBM, and that there is likely to be a relatively wide therapeutic window.

Combining fluoxetine with TMZ suppresses GBM recurrence and prolongs survival

Currently, most patients with GBM, including those with *EGFRvIII* amplification, are treated with the alkylating chemotherapy TMZ, in addition to surgery and radiotherapy. Although the effects of fluoxetine monotherapy were clear, they were not overwhelming, and we hypothesized that fluoxetine might synergize




Figure 3. By increasing sphingomyelin levels, fluoxetine causes loss of cell surface EGFR from membrane rafts with subsequent receptor internalization and degradation

(A and B) Laurdan imaging analysis of membrane lipid order in U87EGFRvIII cells at baseline, after fluoxetine treatment, and with overexpression of an *SMPD1* construct. Generalized polarization (GP) images indicate higher membrane order (red) and lower membrane order (blue). Scale bar, 20 μ m. (C and D) Imaging and flow cytometry analysis (n = 3) of cell surface EGFR in GBM cells. Scale bar, 10 μ m. (E) EGFRvIII and marker proteins in the membrane fractions of GBM39 cells. Calnexin is a marker for non-lipid rafts fractions, while $G\alpha(q)$ and Flotillin-1 are markers of lipid rafts. (F) Percentage of indicated protein levels in fraction 1, the lipid rafts fraction, which is absent with non-lipid rafts marker Calnexin and present with lipid raft markers $G\alpha(q)$ and Flotillin-1. Data were normalized to total protein levels of all six fractions (n = 3). (G) Internalized EGFR of GBM39 cells by flow cytometry (n = 4). (H) EGFR signaling in GBM39 cells treated with sphingomyelins or vehicle. (I) EGFR staining in GBM39 cells with SM d18:1/n16:0 treatment. Scale bar, 10 μ m. (J) Schematic model of the fluoxetine-SMPD1 axis in regulating sphingomyelin metabolism and oncogenic receptor signaling of GBM cells. Data represent mean \pm SD. Two-tailed Student's t test (D, F, and I). ANOVA with Tukey's multiple comparisons test (G). *p < 0.05, ***p < 0.001. See also Figure S5.

TMZ because of the potential role for EGFR signaling in regulating DNA damage repair (Squatrino and Holland, 2011). We also found that fluoxetine treatment resulted in the downregulation of genes in DNA repair pathways in GBM cells (Figures S7A and S7B). *In vitro*, fluoxetine was highly synergistic with TMZ in inducing DNA damage and cell death in multiple GBM models (Figures 5A–5C and S7C–S7J). This combination effect was mediated through downstream EGFRvIII signaling because the AKT E17A-CA allele rescued the cell death (Figure 5C).

Therefore, we compared daily oral fluoxetine treatment alone or in combination with TMZ treatment for 5 days, followed by maintenance on just fluoxetine (Figure 5D). In the GBM39 orthotopic model, daily fluoxetine was as effective as a 5-day course of daily TMZ at inhibiting tumor growth and prolonging mouse survival (Figures 5E–5G), and the impact of combination therapy

was marked. Continuous daily oral 10 mg/kg fluoxetine treatment, in addition to a 5-day course of TMZ, resulted in prolonged suppression of tumor growth (Figures 5D–5F). Most importantly, mouse survival of the group with 5 mg/kg TMZ combination therapy more than doubled (p = 0.0011), with two of six mice showing no tumor recurrence at all after 10 weeks of treatment (Figures 5G and S7K). In the 20 mg/kg TMZ combination therapy group, six of eight mice showed no tumor recurrence at all after 5 months of treatment (Figures 5G, S7L, and S7M). No evidence of systemic or neural toxicity, no weight loss, and no cell death or elevation of LAMP1 in the surrounding brain was detected. Taken together, these data suggest that adding fluoxetine at a clinically demonstrated safe dose to standard-of-care TMZ, followed by fluoxetine maintenance, could have a major effect on tumor progression, recurrence, and survival.




Figure 4. Fluoxetine promotes tumor regression and prolongs survival of mice bearing patient-derived orthotopic GBMs

(A) Schematic of the fluoxetine treatment protocol in patient-derived GBM orthotopic xenograft mouse models.

(B and C) Tumor signal intensity (B) and Kaplan-Meier survival analysis (C) of patient-derived GBM39 orthotopic xenograft models with vehicle or fluoxetine administration ($n = 6$, p.o., daily). Safety doses of fluoxetine for human non-cancer indications were converted to mouse doses based on body surface area. 4.2 and 16.4 mg/kg in mice are equal to the minimal and maximal suggested dose for human indications, respectively.

(D and E) Representative tumor images at week 15 (D) and tumor signal intensity (E) of patient-derived HK296 orthotopic xenograft models with vehicle or fluoxetine administrations ($n = 8$, orally [p.o.], daily). Scale bar, 5 mm. The median value (center line), the minimum (min) and maximum (max) (whiskers), and the 25th and 75th percentiles (box perimeters) are presented.

(F) Percentage of Ki67-positive cells in HK296 xenograft tumors.

(G) Percentage of TUNEL-positive cells in HK296 xenograft tumors and surrounding mouse brains.

(H) Kaplan-Meier survival analysis of mice bearing HK296 xenograft tumors ($n = 8$).

(I–K) Immunohistochemistry analysis of two biomarkers, phosphorylated EGFR and LAMP1, in HK296 xenograft tumors. Scale bar, 50 μm .

Data represent mean \pm SD (B) or mean \pm SEM (F, G, J, and K). ANOVA with Tukey's multiple comparisons test (B, E–G, J, and K). Log rank test (C and H). * $p < 0.05$, ** $p < 0.01$, *** $p < 0.001$, **** $p < 0.0001$. See also Figure S6.

Combining fluoxetine with standard-of-care treatment improves the survival of patients with brain tumor

Realizing that fluoxetine has been prescribed for years, we wondered whether we could find “real-world evidence” that exists in the electronic medical records. We started by examining

electronic medical records from the IBM MarketScan insurance claims dataset (2003–2017), which documents healthcare encounters of over 180 million American enrollees. The ascertained death status was available for 378,685 enrollees. Because GBM is a rare condition, and because we used very stringent exclusion




Figure 5. Combining fluoxetine with temozolomide suppresses GBM recurrence and prolongs survival

(A) Synergistic effect of fluoxetine and temozolomide (TMZ) in U87EGFRvIII cells (n = 4).
 (B) γ H2AX staining in GBM neurospheres. 2.5 μ M for fluoxetine, and 50 μ M for TMZ. Scale bar, 10 μ m.
 (C) Percentage of Annexin V-positive U87EGFRvIII cells (n = 4). 2.5 μ M for fluoxetine, and 50 μ M for TMZ.
 (D) Schematic overview of the fluoxetine-TMZ combination therapy in patient-derived GBM39 orthotopic xenograft models.
 (E–G) Tumor signal intensity (E), representative tumor images at week 5 (F), and Kaplan-Meier survival analysis (G) of patient-derived GBM39 orthotopic xenograft models with indicated administrations (n = 6 or 8 mice per group). Scale bar, 5 mm.
 Data represent mean \pm SD. ANOVA with Tukey’s multiple comparisons test (C and E). Log rank test for survival and Fisher’s exact test for tumor recurrence (G). ***p < 0.001. See also Figure S7.

criteria to identify patients with and without SSRI treatment, the sample size of actual analysis was n = 238; we choose to sacrifice statistical power over quality.

We started by looking for patients who have an ICD9 or ICD10 (International Classification of Diseases) code for “malignant neoplasm of brain” (Table S2), are over the age of 18 years, and lack any other cancers that could be metastatic. We then looked only for adult patients who had surgical resection of the tumor along with radiation therapy and TMZ, to ensure that we are looking at patients with GBM (Figure 6A; Tables S3 and S4). For a final cohort of 238 patients with GBM, we estimated survival probability and hazard ratio of all-cause deaths with and without SSRI exposure after controlling for age, sex, 6-month baseline pre-GBM comorbidities, and also for immortal time bias (Lévesque et al., 2010; Suissa, 2008). We found that patients who had fluoxetine added to standard of care had significantly longer median overall survival (fluoxetine versus control: 545 versus 318 days). The age, sex, and baseline comor-

bidity score adjusted hazard ratio of all-cause death in the fluoxetine-treated group was 0.42 (95% confidence interval [CI], 0.20–0.88; p = 0.022) compared with those not treated with any of the three SSRIs considered in this study (Figure 6B; Table S5). This survival benefit was not found in patients treated with two other SSRIs, citalopram and escitalopram (Figures 6C and 6D; Table S5), which were also shown not to have activity against glioma cell lines (Figure 2), further suggesting the anti-GBM activity of fluoxetine is independent of its function as an SSRI and pointing to the unique anti-GBM activity of fluoxetine. To account for all addressable (represented in data) confounders in our observational analysis, we further performed a stricter propensity score-matched analysis of SSRI-treated and non-treated patients with GBM, accounting for age, sex, and baseline comorbidities (Table S4). As a result of this stricter 1:2 matching (each SSRI-treated patient is matched to two non-SSRI-treated patients), the matched cohort size shrunk, but the survival benefit of fluoxetine against GBM became even stronger (hazard




Figure 6. Real-world electronic medical record evidence for efficacy and specificity: combining fluoxetine, but not citalopram or escitalopram, significantly prolongs survival of patients with brain tumor

(A) Outline of the strategy utilized for definition and enrichment of GBM patient cohort in electronic medical records from the IBM MarketScan dataset (2003–2017).

(B–D) Survival curve of patients in the GBM-enriched cohort treated with fluoxetine (B) and two other SSRI antidepressants, citalopram (C) and escitalopram (D), using time-dependent Kaplan-Meier curves. The adjusted hazards ratio was obtained from the extended Cox proportional hazards model after adjusting for age, sex, and 6-month baseline comorbidities and using SSRI antidepressant treatment as a time-dependent variable.

See also [Figure S7](#) and [Tables S2–S6](#).

ratio of 0.33 [95% CI, 0.13–0.86]) and remained statistically significant ($p = 0.023$) ([Table S6](#)). These results suggest that a combination of fluoxetine with standard-of-care treatment may help to improve the survival of patients with brain tumor ([Figure S7N](#)).

DISCUSSION

GBM has one of the most well-characterized mutational landscapes of any cancer type. Tumors with amplified, bona fide, growth-promoting oncogenes occur in over 50% of GBMs, pre-

senting extremely compelling drug targets. However, the therapeutic promise of precision oncology has yet to be realized for patients with GBM. The challenges include: (1) the poor brain/plasma ratio of many targeted cancer drugs that results in dose-limiting toxicities that preclude effective target inhibition, (2) the unique physiology of the central nervous system that contributes to tumor progression in ways that are only beginning to be understood ([Bi et al., 2020](#); [Quail and Joyce, 2017](#)), and (3) the frequency of ecDNA amplification in GBM and the rapid and reversible dynamics it causes collectively create significant therapeutic challenges. The hoped-for new GBM drugs, FDA approvals, and better

outcomes for patients have yet to materialize. Here, by identifying the enhanced dependence of GBMs on SMPD1, showing how it is required for regulating plasma membrane dynamics and oncogenic signaling, and showing that fluoxetine, which has remarkably favorable pharmacokinetic properties and ability to effectively inhibit SMPD1 enzymatic activity, reveals a unique ability among SSRI antidepressants that can translate into benefit for patients. We have identified a potentially effective new way of treating GBM with a safe, repurposed, FDA-approved drug and determined the molecular mechanistic basis underlying it.

Antidepressants are commonly used in medical practice. As we have shown here, fluoxetine differs from other SSRIs with vastly differing effects on patient survival and on inhibiting oncogenic EGFR signaling. Therefore, it is not surprising that the two major studies that have looked at the effect of antidepressants on the outcome in patients with GBM did not find a significant signal; they did not distinguish among SSRIs (Caudill et al., 2011; Otto-Meyer et al., 2020). In fact, FDA leadership recently suggested that real-world evidence derived from data sources such as electronic health records and insurance databases may have an important role in complementing, but not replacing, randomized controlled clinical trials (Corrigan-Curay et al., 2018; Jarow et al., 2017; Sherman et al., 2016). Incorporating this type of clinical evidence greatly strengthens the mechanistic and mouse model data we provide, nominating fluoxetine in combination with standard of care as a treatment for GBM and suggesting the need for randomized clinical trials in the near term.

Our paper also provides new and unique insight into the critical dependency of GBMs on SMPD1 and its impact on plasma membrane dynamics, including EGFR signaling. We find a critical link between sphingomyelin metabolism and oncogenic receptor signaling on the plasma membrane of GBM cells. Lipids function as essential components of the plasma membrane, and their compositions are precisely regulated in forming signal microdomains (Lingwood and Simons, 2010; Sezgin et al., 2017; van Meer et al., 2008). Fluoxetine, by blocking SMPD1, causes sphingomyelin to accumulate, resulting in the loss of EGFR receptors from lipid rafts domains and from the cell surface of tumor cells. Interestingly, inhibiting SMPD1 was reported to similarly cause KRAS loss from the plasma membrane of MDCK cells (Cho et al., 2015). Therefore, it will be important in the future to determine whether other amplified growth factor receptors similarly induce SMPD1 dependency in GBM and other cancers. Further, sphingomyelins show interaction with cholesterol in the plasma membrane in regulating membrane properties and many intracellular signaling processes (Das et al., 2014; Endapally et al., 2019; Lingwood and Simons, 2010). SMPD1-mediated sphingomyelin metabolism alters the accessible cholesterol pool of the plasma membrane (Das et al., 2014; Endapally et al., 2019), indicating a potential role of membrane cholesterol in the fluoxetine-SMPD1-EGFR axis. This result is consistent with our previous findings that amplified growth factor receptors in GBM may generate a metabolic dependency on cholesterol and saturated phospholipids (Bi et al., 2019, 2020; Villa et al., 2016).

Fluoxetine was initially developed and approved as a SSRI for patients with depression (Wong et al., 2005), and it has been recently shown to inhibit SMPD1 enzymatic activity in some con-

texts (Gulbins et al., 2013; Kornhuber et al., 2008). Our data in GBM tumor cells indicate that fluoxetine blocks over 60% of SMPD1 enzymatic activity within 6 h and may act as an indirect inhibitor of EGFR by blocking SMPD1 and elevating sphingomyelin levels. Complete germline loss of *SMPD1* causes lysosomal storage disorders because of excess sphingomyelins on the lysosomal membrane (Schuchman and Desnick, 2017). Lysosomal stress that was detected in GBM tumor cells treated with fluoxetine may also contribute to tumor cell death (Peterson et al., 2013) and may be a main mechanism of sensitization in non-EGFR-driven GBMs. Indeed, we found that GBM cells of many different mutational backgrounds were highly sensitive to fluoxetine, although not quite as sensitive as tumor cells containing amplified EGFRvIII or wild-type EGFR. We hypothesize that this sensitivity is mediated through lysosomal stress, which merits further study. Further, besides the DNA repair pathway, other downstream pathways may also potentially contribute to the sensitivity of GBM cells to fluoxetine-TMZ combination therapy (Ma et al., 2016).

Limitations of the study

GBMs exhibit considerable intratumoral, cellular genetic, and biochemical heterogeneity. Individual cells within *EGFRvIII*-amplified tumors can vary in EGFRvIII DNA, RNA, and protein levels, which may impact downstream signaling and the sensitivity to fluoxetine. Although our data show dramatic effects in models that capture this heterogeneity, we cannot exclude that there are likely differences in cell-to-cell response. We focused on *EGFR/EGFRvIII* amplification because it is the most commonly amplified RTK in GBMs. However, our focus on EGFR/EGFRvIII limited our analysis of other RTKs. Future studies will be needed to completely understand the spectrum of patients with GBM who could potentially benefit from fluoxetine treatment.

Real-world evidence is retrospective and may contain potential biases. For example, in our study, the electronic medical records were from patients who died in the hospital. This accounts for a small fraction of patients with GBM and may be related to the relatively shorter median survival of patients treated with standard of care in this cohort than often seen. The number of patients taking fluoxetine after GBM diagnosis also limited our interpretation of its clinical impact. A well-controlled, prospective, randomized clinical trial will be needed to determine whether addition of fluoxetine to standard-of-care treatment improves survival of patients with GBM and to optimize dosing.

STAR★METHODS

Detailed methods are provided in the online version of this paper and include the following:

- KEY RESOURCES TABLE
- RESOURCE AVAILABILITY
 - Lead contact
 - Materials availability
 - Data and code availability
- EXPERIMENTAL MODEL AND SUBJECT DETAILS

- Cell lines
- Intracranial GBM xenograft models
- **METHOD DETAILS**
 - Gene expression and shRNA transduction
 - DepMap data analysis
 - Sphingolipid analysis by LC-MS
 - Sphingomyelin (d18:1/n16:0-d9) metabolomics
 - SMPD1 enzymatic activity assay
 - Cell viability assay
 - Cell death and Annexin V-positive cell analysis
 - Soft-agar colony formation assay
 - Crystal violet clonogenic assay
 - RNA extraction and qRT-PCR
 - Immunofluorescence staining
 - Drug and lipid treatment
 - Membrane lipid order imaging of live cells
 - Western blot analysis
 - Immunohistochemistry analysis
 - Cell surface EGFR and internalization analysis
 - Density gradient fractionation
 - RNA-seq analysis
 - TCGA data analysis
 - Patient survival in Electronic Medical Records
- **QUANTIFICATION AND STATISTICAL ANALYSIS**

SUPPLEMENTAL INFORMATION

Supplemental information can be found online at <https://doi.org/10.1016/j.celrep.2021.109957>.

ACKNOWLEDGMENTS

This work was supported by grants from the National Institute for Neurological Diseases and Stroke (NS73831 and NS080939), the Defeat GBM Program of the National Brain Tumor Society, the Ben and Catherine Ivy Foundation, an award from the Sharpe/National Brain Tumor Society Research Program, a Compute for the Cure Award from the Nvidia Foundation (P.S.M.), and a UCSD Neuroscience Microscopy Shared Facility Grant (P30 NS047101). P.S.M. dedicates this paper to Bob Sharpe, a friend and remarkable person who, during his battle with GBM, courageously and gracefully taught him so much about living.

AUTHOR CONTRIBUTIONS

J.B. and P.S.M. conceived the study and designed all experiments. J.B., J.T., I.T.-L.W., A.R., H.J., Y.G., and H.Y. performed experiments. A.K. and A.R. analyzed patient datasets from electronic medical records. J.B., S.W., W.Z., R.C.G., and B.P. performed the bioinformatics analysis. J.B., J.T., T.K., S.M., and E.J.C. contributed to the mouse experiments. A.M.A. and O.Q. performed the lipidomics analysis. H.I.K. and F.B.F. provided cell lines or reagents and intellectual input. D.A.W., T.F.C., J.N.R., and B.F.C. provided intellectual input. J.B., W.Z., A.M.A., O.Q., B.F.C., and P.S.M. analyzed and interpreted data. J.B. and P.S.M. wrote the manuscript, and all authors edited and approved the manuscript.

DECLARATION OF INTERESTS

P.S.M. is co-founder of Boundless Bio, Inc. He has equity in the company, chairs the scientific advisory board, and serves as a consultant, for which he is compensated. P.S.M. is also consultant for Autobahn Therapeutics, Inc. and Sage Therapeutics. These consulting arrangements started after completion of this paper.

Received: March 10, 2021
Revised: September 10, 2021
Accepted: October 15, 2021
Published: November 2, 2021

REFERENCES

- Andersen, P.K., and Gill, R.D. (1982). Cox regression-model for counting-processes: a large sample study. *Ann. Stat.* *10*, 1100–1120.
- Arhipov, A., Shan, Y., Das, R., Endres, N.F., Eastwood, M.P., Wemmer, D.E., Kuriyan, J., and Shaw, D.E. (2013). Architecture and membrane interactions of the EGF receptor. *Cell* *152*, 557–569.
- Bi, J., Ichu, T.A., Zanca, C., Yang, H., Zhang, W., Gu, Y., Chowdhry, S., Reed, A., Ikegami, S., Turner, K.M., et al. (2019). Oncogene amplification in growth factor signaling pathways renders cancers dependent on membrane lipid remodeling. *Cell Metab.* *30*, 525–538.e8.
- Bi, J., Chowdhry, S., Wu, S., Zhang, W., Masui, K., and Mischel, P.S. (2020). Altered cellular metabolism in gliomas - an emerging landscape of actionable co-dependency targets. *Nat. Rev. Cancer* *20*, 57–70.
- Bindea, G., Mlecnik, B., Hackl, H., Charoentong, P., Tosolini, M., Kirilovsky, A., Fridman, W.H., Pagès, F., Trajanoski, Z., and Galon, J. (2009). ClueGO: a Cytoscape plug-in to decipher functionally grouped gene ontology and pathway annotation networks. *Bioinformatics* *25*, 1091–1093.
- Bolo, N.R., Hodé, Y., Nédélec, J.F., Lainé, E., Wagner, G., and Macher, J.P. (2000). Brain pharmacokinetics and tissue distribution in vivo of fluvoxamine and fluoxetine by fluorine magnetic resonance spectroscopy. *Neuropsychopharmacology* *23*, 428–438.
- Brennan, C.W., Verhaak, R.G., McKenna, A., Campos, B., Nounshmeir, H., Salama, S.R., Zheng, S., Chakravarty, D., Sanborn, J.Z., Berman, S.H., et al.; TCGA Research Network (2013). The somatic genomic landscape of glioblastoma. *Cell* *155*, 462–477.
- Buczkwicz, P., Hoeman, C., Rakopoulos, P., Pajovic, S., Letourneau, L., Dzamba, M., Morrison, A., Lewis, P., Bouffet, E., Bartels, U., et al. (2014). Genomic analysis of diffuse intrinsic pontine gliomas identifies three molecular subgroups and recurrent activating ACVR1 mutations. *Nat. Genet.* *46*, 451–456.
- Caudill, J.S., Brown, P.D., Cerhan, J.H., and Rummans, T.A. (2011). Selective serotonin reuptake inhibitors, glioblastoma multiforme, and impact on toxicities and overall survival: the mayo clinic experience. *Am. J. Clin. Oncol.* *34*, 385–387.
- Cerami, E., Gao, J., Dogrusoz, U., Gross, B.E., Sumer, S.O., Aksoy, B.A., Jacobsen, A., Byrne, C.J., Heuer, M.L., Larsson, E., et al. (2012). The cBio cancer genomics portal: an open platform for exploring multidimensional cancer genomics data. *Cancer Discov.* *2*, 401–404.
- Cho, K.J., van der Hoeven, D., Zhou, Y., Maekawa, M., Ma, X., Chen, W., Fair, G.D., and Hancock, J.F. (2015). Inhibition of Acid Sphingomyelinase Depletes Cellular Phosphatidylserine and Mislocalizes K-Ras from the Plasma Membrane. *Mol. Cell. Biol.* *36*, 363–374.
- Cizmecioglu, O., Ni, J., Xie, S., Zhao, J.J., and Roberts, T.M. (2016). Rac1-mediated membrane raft localization of PI3K/p110 β is required for its activation by GPCRs or PTEN loss. *eLife* *5*, e17635.
- Cloughesy, T.F., Cavenee, W.K., and Mischel, P.S. (2014). Glioblastoma: from molecular pathology to targeted treatment. *Annu. Rev. Pathol.* *9*, 1–25.
- Corrigan-Curay, J., Sacks, L., and Woodcock, J. (2018). Real-World Evidence and Real-World Data for Evaluating Drug Safety and Effectiveness. *JAMA* *320*, 867–868.
- Corsello, S.M., Nagari, R.T., Spangler, R.D., Rossen, J., Kocak, M., Bryan, J.G., Humeidi, R., Peck, D., Wu, X., Tang, A.A., et al. (2020). Discovering the anti-cancer potential of non-oncology drugs by systematic viability profiling. *Nat. Can.* *1*, 235–248.
- Das, A., Brown, M.S., Anderson, D.D., Goldstein, J.L., and Radhakrishnan, A. (2014). Three pools of plasma membrane cholesterol and their relation to cholesterol homeostasis. *eLife* *3*, e02882.

- Broad DepMap (2020). DepMap 20Q1 Public. figshare. https://figshare.com/articles/dataset/DepMap_20Q1_Public/11791698/2.
- Dolma, S., Selvadurai, H.J., Lan, X., Lee, L., Kushida, M., Voisin, V., Whetstone, H., So, M., Aviv, T., Park, N., et al. (2016). Inhibition of Dopamine Receptor D4 Impedes Autophagic Flux, Proliferation, and Survival of Glioblastoma Stem Cells. *Cancer Cell* 29, 859–873.
- Eli Lilly and Company (2017). PROZAC (fluoxetine) [package insert]. (US Food and Drug Administration). https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/018936s1081bl.pdf.
- Endapally, S., Frias, D., Grzemska, M., Gay, A., Tomchick, D.R., and Radhakrishnan, A. (2019). Molecular Discrimination between Two Conformations of Sphingomyelin in Plasma Membranes. *Cell* 176, 1040–1053.e17.
- Gao, J., Aksoy, B.A., Dogrusoz, U., Dresdner, G., Gross, B., Sumer, S.O., Sun, Y., Jacobsen, A., Sinha, R., Larsson, E., et al. (2013). Integrative analysis of complex cancer genomics and clinical profiles using the cBioPortal. *Sci. Signal.* 6, pii1.
- Ghandi, M., Huang, F.W., Jané-Valbuena, J., Kryukov, G.V., Lo, C.C., McDonald, E.R., 3rd, Barretina, J., Gelfand, E.T., Bielski, C.M., Li, H., et al. (2019). Next-generation characterization of the Cancer Cell Line Encyclopedia. *Nature* 569, 503–508.
- Grambsch, P.M., and Therneau, T.M. (1994). Proportional Hazards Tests and Diagnostics Based on Weighted Residuals. *Biometrika* 81, 515–526.
- Gulbins, E., Palmada, M., Reichel, M., Lüth, A., Böhrer, C., Amato, D., Müller, C.P., Tischbirek, C.H., Groemer, T.W., Tabatabai, G., et al. (2013). Acid sphingomyelinase-ceramide system mediates effects of antidepressant drugs. *Nat. Med.* 19, 934–938.
- Guo, D., Reinitz, F., Youssef, M., Hong, C., Nathanson, D., Akhavan, D., Kuga, D., Amzajerdi, A.N., Soto, H., Zhu, S., et al. (2011). An LXR agonist promotes glioblastoma cell death through inhibition of an EGFR/AKT/SREBP-1/LDLR-dependent pathway. *Cancer Discov.* 1, 442–456.
- Hannun, Y.A., and Obeid, L.M. (2018). Sphingolipids and their metabolism in physiology and disease. *Nat. Rev. Mol. Cell Biol.* 19, 175–191.
- Hu, B., Wang, Q., Wang, Y.A., Hua, S., Sauvé, C.G., Ong, D., Lan, Z.D., Chang, Q., Ho, Y.W., Monasterio, M.M., et al. (2016). Epigenetic Activation of WNT5A Drives Glioblastoma Stem Cell Differentiation and Invasive Growth. *Cell* 167, 1281–1295.e18.
- IBM Watson Health (2018). IBM MarketScan Research Databases for Life Sciences Researchers (white paper). <https://www.ibm.com/downloads/cas/0NKLE57Y>.
- Jarow, J.P., LaVange, L., and Woodcock, J. (2017). Multidimensional Evidence Generation and FDA Regulatory Decision Making: Defining and Using “Real-World” Data. *JAMA* 318, 703–704.
- Kaplan, E.L., and Meier, P. (1958). Nonparametric–Estimation from Incomplete Observations. *J. Am. Stat. Assoc.* 53, 457–481.
- Karson, C.N., Newton, J.E., Livingston, R., Jolly, J.B., Cooper, T.B., Sprigg, J., and Komoroski, R.A. (1993). Human brain fluoxetine concentrations. *J. Neuropsychiatry Clin. Neurosci.* 5, 322–329.
- Kim, H., Nguyen, N.P., Turner, K., Wu, S., Gujar, A.D., Luebeck, J., Liu, J., Deshpande, V., Rajkumar, U., Namburi, S., et al. (2020). Extrachromosomal DNA is associated with oncogene amplification and poor outcome across multiple cancers. *Nat. Genet.* 52, 891–897.
- Kobayashi, S., Shimamura, T., Monti, S., Steidl, U., Hetherington, C.J., Lowell, A.M., Golub, T., Meyerson, M., Tenen, D.G., Shapiro, G.I., and Halmos, B. (2006). Transcriptional profiling identifies cyclin D1 as a critical downstream effector of mutant epidermal growth factor receptor signaling. *Cancer Res.* 66, 11389–11398.
- Kornhuber, J., Tripal, P., Reichel, M., Terfloth, L., Bleich, S., Wiltfang, J., and Gulbins, E. (2008). Identification of new functional inhibitors of acid sphingomyelinase using a structure-property-activity relation model. *J. Med. Chem.* 51, 219–237.
- Laks, D.R., Crisman, T.J., Shih, M.Y., Mottahedeh, J., Gao, F., Sperry, J., Garrett, M.C., Yong, W.H., Cloughesy, T.F., Liau, L.M., et al. (2016). Large-scale assessment of the gliomasphere model system. *Neuro-oncol.* 18, 1367–1378.
- Lemmon, M.A., Schlessinger, J., and Ferguson, K.M. (2014). The EGFR family: not so prototypical receptor tyrosine kinases. *Cold Spring Harb. Perspect. Biol.* 6, a020768.
- Lévesque, L.E., Hanley, J.A., Kezouh, A., and Suissa, S. (2010). Problem of immortal time bias in cohort studies: example using statins for preventing progression of diabetes. *BMJ* 340, b5087.
- Lingwood, D., and Simons, K. (2010). Lipid rafts as a membrane-organizing principle. *Science* 327, 46–50.
- Love, M.I., Huber, W., and Anders, S. (2014). Moderated estimation of fold change and dispersion for RNA-seq data with DESeq2. *Genome Biol.* 15, 550.
- Lu, Y., Li, X., Liang, K., Luwor, R., Siddik, Z.H., Mills, G.B., Mendelsohn, J., and Fan, Z. (2007). Epidermal growth factor receptor (EGFR) ubiquitination as a mechanism of acquired resistance escaping treatment by the anti-EGFR monoclonal antibody cetuximab. *Cancer Res.* 67, 8240–8247.
- Luwor, R.B., Johns, T.G., Murone, C., Huang, H.J., Cavenee, W.K., Ritter, G., Old, L.J., Burgess, A.W., and Scott, A.M. (2001). Monoclonal antibody 806 inhibits the growth of tumor xenografts expressing either the de2-7 or amplified epidermal growth factor receptor (EGFR) but not wild-type EGFR. *Cancer Res.* 61, 5355–5361.
- Ma, J., Yang, Y.R., Chen, W., Chen, M.H., Wang, H., Wang, X.D., Sun, L.L., Wang, F.Z., and Wang, D.C. (2016). Fluoxetine synergizes with temozolomide to induce the CHOP-dependent endoplasmic reticulum stress-related apoptosis pathway in glioma cells. *Oncol. Rep.* 36, 676–684.
- Macdonald, J.L., and Pike, L.J. (2005). A simplified method for the preparation of detergent-free lipid rafts. *J. Lipid Res.* 46, 1061–1067.
- Mack, S.C., Hubert, C.G., Miller, T.E., Taylor, M.D., and Rich, J.N. (2016). An epigenetic gateway to brain tumor cell identity. *Nat. Neurosci.* 19, 10–19.
- Mahé, C., Bernhard, M., Bobirac, I., Keser, C., Loetscher, E., Feuerbach, D., Dev, K.K., and Schoeffter, P. (2004). Functional expression of the serotonin 5-HT7 receptor in human glioblastoma cell lines. *Br. J. Pharmacol.* 143, 404–410.
- McFarland, J.M., Ho, Z.V., Kugener, G., Dempster, J.M., Montgomery, P.G., Bryan, J.G., Krill-Burger, J.M., Green, T.M., Vazquez, F., Boehm, J.S., et al. (2018). Improved estimation of cancer dependencies from large-scale RNAi screens using model-based normalization and data integration. *Nat. Commun.* 9, 4610.
- Morton, A.R., Dogan-Artun, N., Faber, Z.J., MacLeod, G., Bartels, C.F., Piazza, M.S., Allan, K.C., Mack, S.C., Wang, X., Gimple, R.C., et al. (2019). Functional Enhancers Shape Extrachromosomal Oncogene Amplifications. *Cell* 179, 1330–1341.e13.
- Nagaraja, S., Quezada, M.A., Gillespie, S.M., Arzt, M., Lennon, J.J., Woo, P.J., Hovestadt, V., Kambhampati, M., Filbin, M.G., Suva, M.L., et al. (2019). Histone Variant and Cell Context Determine H3K27M Reprogramming of the Enhancer Landscape and Oncogenic State. *Mol. Cell* 76, 965–980.e12.
- Nathanson, D.A., Gini, B., Mottahedeh, J., Visnyei, K., Koga, T., Gomez, G., Eskin, A., Hwang, K., Wang, J., Masui, K., et al. (2014). Targeted therapy resistance mediated by dynamic regulation of extrachromosomal mutant EGFR DNA. *Science* 343, 72–76.
- Nikolaev, S., Santoni, F., Garieri, M., Makrythanasis, P., Falconnet, E., Guipponi, M., Vannier, A., Radovanovic, I., Bena, F., Forestier, F., et al. (2014). Extrachromosomal driver mutations in glioblastoma and low-grade glioma. *Nat. Commun.* 5, 5690.
- Noack, J., Choi, J., Richter, K., Kopp-Schneider, A., and Régnier-Vigouroux, A. (2014). A sphingosine kinase inhibitor combined with temozolomide induces glioblastoma cell death through accumulation of dihydrosphingosine and dihydroceramide, endoplasmic reticulum stress and autophagy. *Cell Death Dis.* 5, e1425.
- Nusinow, D.P., Szpyt, J., Ghandi, M., Rose, C.M., McDonald, E.R., 3rd, Kalocsay, M., Jané-Valbuena, J., Gelfand, E., Schweppe, D.K., Jedrychowski, M., et al. (2020). Quantitative Proteomics of the Cancer Cell Line Encyclopedia. *Cell* 180, 387–402.e16.
- Ogretmen, B. (2018). Sphingolipid metabolism in cancer signalling and therapy. *Nat. Rev. Cancer* 18, 33–50.

- Otto-Meyer, S., DeFaccio, R., Dussold, C., Ladomersky, E., Zhai, L., Lauing, K.L., Bollu, L.R., Amidei, C., Lukas, R.V., Scholtens, D.M., and Wainwright, D.A. (2020). A retrospective survival analysis of Glioblastoma patients treated with selective serotonin reuptake inhibitors. *Brain Behav. Immun. Health* **2**, 100025.
- Owen, D.M., Rentero, C., Magenau, A., Abu-Siniyeh, A., and Gaus, K. (2011). Quantitative imaging of membrane lipid order in cells and organisms. *Nat. Protoc.* **7**, 24–35.
- Parasassi, T., Gratton, E., Yu, W.M., Wilson, P., and Levi, M. (1997). Two-photon fluorescence microscopy of laurdan generalized polarization domains in model and natural membranes. *Biophys. J.* **72**, 2413–2429.
- Patro, R., Duggal, G., Love, M.I., Irizarry, R.A., and Kingsford, C. (2017). Salmon provides fast and bias-aware quantification of transcript expression. *Nat. Methods* **14**, 417–419.
- Petersen, N.H., Olsen, O.D., Groth-Pedersen, L., Ellegaard, A.M., Bilgin, M., Redmer, S., Ostenfeld, M.S., Ulanet, D., Dovmark, T.H., Lønborg, A., et al. (2013). Transformation-associated changes in sphingolipid metabolism sensitize cells to lysosomal cell death induced by inhibitors of acid sphingomyelinase. *Cancer Cell* **24**, 379–393.
- Quail, D.F., and Joyce, J.A. (2017). The Microenvironmental Landscape of Brain Tumors. *Cancer Cell* **31**, 326–341.
- Sanchez-Vega, F., Mina, M., Armenia, J., Chatila, W.K., Luna, A., La, K.C., Dimitriadou, S., Liu, D.L., Kantheti, H.S., Saghafein, S., et al.; Cancer Genome Atlas Research Network (2018). Oncogenic Signaling Pathways in The Cancer Genome Atlas. *Cell* **173**, 321–337.e10.
- Schoenfeld, D. (1980). Chi-Squared Goodness-of-Fit Tests for the Proportional Hazards Regression Model. *Biometrika* **67**, 145–153.
- Schuchman, E.H. (2010). Acid sphingomyelinase, cell membranes and human disease: lessons from Niemann-Pick disease. *FEBS Lett.* **584**, 1895–1900.
- Schuchman, E.H., and Desnick, R.J. (2017). Types A and B Niemann-Pick disease. *Mol. Genet. Metab.* **120**, 27–33.
- Sezgin, E., Levental, I., Mayor, S., and Eggeling, C. (2017). The mystery of membrane organization: composition, regulation and roles of lipid rafts. *Nat. Rev. Mol. Cell Biol.* **18**, 361–374.
- Sherman, R.E., Anderson, S.A., Dal Pan, G.J., Gray, G.W., Gross, T., Hunter, N.L., LaVange, L., Marinac-Dabic, D., Marks, P.W., Robb, M.A., et al. (2016). Real-World Evidence - What Is It and What Can It Tell Us? *N. Engl. J. Med.* **375**, 2293–2297.
- Squatrito, M., and Holland, E.C. (2011). DNA damage response and growth factor signaling pathways in gliomagenesis and therapeutic resistance. *Cancer Res.* **71**, 5945–5949.
- Subramanian, A., Tamayo, P., Mootha, V.K., Mukherjee, S., Ebert, B.L., Gillette, M.A., Paulovich, A., Pomeroy, S.L., Golub, T.R., Lander, E.S., and Mesirov, J.P. (2005). Gene set enrichment analysis: a knowledge-based approach for interpreting genome-wide expression profiles. *Proc. Natl. Acad. Sci. USA* **102**, 15545–15550.
- Suissa, S. (2007). Immortal time bias in observational studies of drug effects. *Pharmacoepidemiol. Drug Saf.* **16**, 241–249.
- Suissa, S. (2008). Immeasurable time bias in observational studies of drug effects on mortality. *Am. J. Epidemiol.* **168**, 329–335.
- Tang, Z., Li, C., Kang, B., Gao, G., Li, C., and Zhang, Z. (2017). GEPIA: a web server for cancer and normal gene expression profiling and interactive analyses. *Nucleic Acids Res.* **45** (W1), W98–W102.
- Therneau, T.M., and Grambsch, P.M. (2000). The Cox Model. In *Modeling Survival Data: Extending the Cox Model* (Springer), pp. 39–77.
- Therneau, T.M., and Lumley, T. (2015). Package ‘survival’ (R Top Doc).
- Turner, K.M., Deshpande, V., Beyter, D., Koga, T., Rusert, J., Lee, C., Li, B., Arden, K., Ren, B., Nathanson, D.A., et al. (2017). Extrachromosomal oncogene amplification drives tumour evolution and genetic heterogeneity. *Nature* **543**, 122–125.
- van Diggelen, O.P., Voznyi, Y.V., Keulemans, J.L., Schoonderwoerd, K., Ledvinova, J., Mengel, E., Zschiesche, M., Santer, R., and Harzer, K. (2005). A new fluorimetric enzyme assay for the diagnosis of Niemann-Pick A/B, with specificity of natural sphingomyelinase substrate. *J. Inher. Metab. Dis.* **28**, 733–741.
- van Meer, G., Voelker, D.R., and Feigenson, G.W. (2008). Membrane lipids: where they are and how they behave. *Nat. Rev. Mol. Cell Biol.* **9**, 112–124.
- Villa, G.R., Hulce, J.J., Zanca, C., Bi, J., Ikegami, S., Cahill, G.L., Gu, Y., Lum, K.M., Masui, K., Yang, H., et al. (2016). An LXR-Cholesterol Axis Creates a Metabolic Co-Dependency for Brain Cancers. *Cancer Cell* **30**, 683–693.
- Wang, M.Y., Lu, K.V., Zhu, S., Dia, E.Q., Vivanco, I., Shackleford, G.M., Cavenee, W.K., Mellinghoff, I.K., Cloughesy, T.F., Sawyers, C.L., and Mischel, P.S. (2006). Mammalian target of rapamycin inhibition promotes response to epidermal growth factor receptor kinase inhibitors in PTEN-deficient and PTEN-intact glioblastoma cells. *Cancer Res.* **66**, 7864–7869.
- Wen, P.Y., Weller, M., Lee, E.Q., Alexander, B.M., Barnholtz-Sloan, J.S., Barthel, F.P., Batchelor, T.T., Bindra, R.S., Chang, S.M., Chiocca, E.A., et al. (2020). Glioblastoma in adults: a Society for Neuro-Oncology (SNO) and European Society of Neuro-Oncology (EANO) consensus review on current management and future directions. *Neuro-oncol.* **22**, 1073–1113.
- Wong, D.T., Perry, K.W., and Bymaster, F.P. (2005). Case history: the discovery of fluoxetine hydrochloride (Prozac). *Nat. Rev. Drug Discov.* **4**, 764–774.
- Xu, K., Ding, L., Chang, T.C., Shao, Y., Chiang, J., Mulder, H., Wang, S., Shaw, T.I., Wen, J., Hover, L., et al. (2019). Structure and evolution of double minutes in diagnosis and relapse brain tumors. *Acta Neuropathol.* **137**, 123–137.
- Zhou, Z., Rahme, E., Abrahamowicz, M., and Pilote, L. (2005). Survival bias associated with time-to-treatment initiation in drug effectiveness evaluation: a comparison of methods. *Am. J. Epidemiol.* **162**, 1016–1023.
- Zhou, Y.H., Chen, Y., Hu, Y., Yu, L., Tran, K., Giedzinski, E., Ru, N., Gau, A., Pan, F., Qiao, J., et al. (2017). The role of EGFR double minutes in modulating the response of malignant gliomas to radiotherapy. *Oncotarget* **8**, 80853–80868.

STAR★METHODS

KEY RESOURCES TABLE

REAGENT or RESOURCE	SOURCE	IDENTIFIER
Antibodies		
Rabbit anti-pEGFR-Y1068, Clone D7A5 (WB 1:1000, IHC 1:800)	Cell Signaling	Cat#3777; RRID:AB_2096270
Rabbit anti-EGFR (WB 1:10000)	Millipore	Cat# 06-847; RRID:AB_2096607
Mouse anti-EGFR (Ab-1), Clone 528 (Flow 1:20)	Millipore	Cat#GR01; RRID:AB_564572
Rabbit anti-EGFR (D38B1) conjugated with Alexa Fluor-488 (IF 1:200)	Cell Signaling	Cat#5616; RRID: AB_10691853
Rabbit Anti-LAMP1, Clone D2D11 (IF and IHC 1:200)	Cell Signaling	Cat#9091; RRID:AB_2687579
Rabbit Anti-LAMP1 (IHC 1:200)	Abcam	Cat#ab24170, RRID:AB_775978
Rabbit Anti-PDGFR α , Clone D1E1E (WB 1:1000)	Cell Signaling	Cat#3174; RRID:AB_2162345
Rabbit Anti-pPDGFR α -Tyr754, Clone 23B2 (WB 1:1000)	Cell Signaling	Cat#2992; RRID:AB_390728
Rabbit Anti-FGFR1, Clone D8E4 (WB 1:1000)	Cell Signaling	Cat#9740; RRID:AB_11178519
Mouse Anti- Phospho-FGF Receptor (Tyr653/654), Clone 55H2 (WB 1:500)	Cell Signaling	Cat#3476; RRID:AB_331369
Rabbit Anti-Met, Clone D1C2 (WB 1:1000)	Cell Signaling	Cat#8198; RRID:AB_10858224
Rabbit Anti-Phospho-Met (Tyr1234/1235), Clone D26 (WB 1:500)	Cell Signaling	Cat#3077; RRID:AB_2143884
Rabbit anti-pAkt-S473, Clone D9E (WB 1:3000)	Cell Signaling	Cat#4060; RRID:AB_2315049
Rabbit anti-pS6-S235/236, Clone D57.2.2E (WB 1:3000, IHC 1:400)	Cell Signaling	Cat#4858; RRID:AB_916156
Mouse Anti-rH2AX/ phosphor-Histone H2A.X (Ser139), Clone JBW301 (IF 1:200)	Millipore	Cat#05-636; RRID:AB_309864
Rabbit anti-Flotillin-1, Clone D2V7J (WB 1:1000)	Cell Signaling	Cat#18634; RRID:AB_2773040
Rabbit anti- G α (q), Clone D5V1B (WB 1:1000)	Cell Signaling	Cat#14373; RRID:AB_2665457
Rabbit anti-Calnexin, Clone C5C9 (WB 1:1000)	Cell Signaling	Cal#2679; RRID:AB_2228381
Mouse anti-actin, Clone AC40 (WB 1:3000)	Sigma	Cat#A4700; RRID:AB_476730
Anti-rabbit IgG, HRP-linked (WB 1:2000)	Cell Signaling	Cat#7074; RRID:AB_2099233
Anti-mouse IgG, HRP-linked (WB 1:2000)	Cell Signaling	Cat#7076; RRID:AB_330924
Alexa Fluor anti-rabbit 546 (IF 1:500)	ThermoFisher Scientific	Cat#A11010; RRID:AB_2534085
Alexa Fluor anti-mouse 488 (Flow and IF 1:500)	ThermoFisher Scientific	Cat#A11017; RRID:AB_2534084
Mouse anti-Ki67, Clone 8D5 (IHC 1:500)	Cell Signaling	Cat#9449; RRID:AB_2797703
Chemicals, peptides, and recombinant proteins		
DMEM	Corning	Cat#10-013
DMEM/F12	GIBCO	Cat#11320-033
Pen Strep Glutamine	GIBCO	Cat#10378-016
Glutamax	GIBCO	Cat#35050-061
B27	GIBCO	Cat#17504-001

(Continued on next page)

Continued

REAGENT or RESOURCE	SOURCE	IDENTIFIER
Fetal Bovine Serum (FBS)	Omega Scientific	Cat#FB-21
Epidermal Growth Factor (EGF)	Sigma	Cat#E9644
Fibroblast Growth Factor (FGF)	Sigma	Cat#F0291
Heparin	Sigma	Cat#H3149
AGM BulletKit	LONZA	Cat#CC-3186
C16 Ceramide (d18:1/16:0)	Avanti Polar Lipids	Cat#860516
16:0 SM (d18:1/16:0)	Avanti Polar Lipids	Cat#860584
24:0 SM (d18:1/24:0)	Avanti Polar Lipids	Cat#860592
SM (d18:1/n16:0-d9)	Cayman Chemical	Cat#30141
SM (d18:1/17:0)	Avanti Polar Lipids	Cat#860585P
Ceramide (d18:1/17:0)	Avanti Polar Lipids	Cat #860517P
Fatty acid-free Bovine Serum Albumin	Sigma	Cat#A6003
MG132	Cell Signaling	Cat#2194
Chloroquine	Cell Signaling	Cat#14774
LysoTracker	Invitrogen	Cat#L7528
Low gelling temperature agarose	Sigma	Cat#A9045
Trypan Blue Solution	GIBCO	Cat#15250061
Opti-Prep Density Gradient Medium	Sigma	Cat#D1556
rTdT	Invitrogen	Cat#10533065
Digoxigenin-11-dUTP	Roche	Cat#11558706910
Anti-Digoxigenin-POD	Roche	Cat#11207733910
Crystal violet solution	Sigma	Cat#V5265
Laurdan (6-Dodecanoyl-2-Dimethylaminonaphthalene)	ThermoFisher Scientific	Cat#D250
Temozolomide	MedChemExpress	Cat#HY-17364
Fluoxetine	MedChemExpress	Cat#HY-B0102A

Critical commercial assays

X-tremeGENE HP DNA Transfection Reagent	Roche	Cat#6366236001
RNeasy Mini Kit	QIAGEN	Cat#74106
SYBR Green Supermix	Bio-Rad	Cat#1708880
BCA Protein Assay Kit	ThermoFisher Scientific	Cat#23225
SuperSignal West Pico PLUS Chemiluminescent Substrate	ThermoFisher Scientific	Cat#34580
FITC Annexin V Apoptosis Detection Kit I	BD Biosciences	Cat#556547
Acid Sphingomyelinase Enzymatic Activity kit	Echelon	Cat#K-3200
CellTiter-Glo	Promega	Cat#G7572

Deposited data

RNA-seq	This study	GEO: GSE158674
Data S1	This study	https://data.mendeley.com/datasets/5gww3pgbj3/1

Experimental models: Cell lines

Human: Normal Human Astrocyte (NHA)	LONZA	CC-2565
Human: IMR90	ATCC	CCL-186
Human: RPE1	ATCC	CRL-4000
Human: U87	ATCC	HTB-14
Human: U87EGFRvIII	Wang et al., 2006	N/A

(Continued on next page)

<i>Continued</i>		
REAGENT or RESOURCE	SOURCE	IDENTIFIER
Human: GBM39 patient-derived neurosphere cells	Nathanson et al., 2014	N/A
Human: HK301 patient-derived neurosphere cells	Laks et al., 2016	N/A
Human: HK296 patient-derived neurosphere cells	Laks et al., 2016	N/A
Human: HK359 patient-derived neurosphere cells	Laks et al., 2016	N/A
Human: HK336 patient-derived neurosphere cells	Laks et al., 2016	N/A
Human: HK217 patient-derived neurosphere cells	Laks et al., 2016	N/A
Human: HK390 patient-derived neurosphere cells	Laks et al., 2016	N/A
Human: HK385 patient-derived neurosphere cells	Laks et al., 2016	N/A
Human: HK254 patient-derived neurosphere cells	Laks et al., 2016	N/A
Human: HK350 patient-derived neurosphere cells	Laks et al., 2016	N/A
Human: HK250 patient-derived neurosphere cells	Laks et al., 2016	N/A
Human: HK229 patient-derived neurosphere cells	Laks et al., 2016	N/A
Human: TS576 patient-derived neurosphere cells	Hu et al., 2016	N/A
Human: CA718 patient-derived neurosphere cells	Turner et al., 2017	N/A
Human: DIPG25 Diffuse Intrinsic Pontine Glioma line	Nagaraja et al., 2019	N/A
Human: DIPG38 Diffuse Intrinsic Pontine Glioma line	Nagaraja et al., 2019	N/A
Human: DIPG36 Diffuse Intrinsic Pontine Glioma line	Nagaraja et al., 2019	N/A
Human: DIPG50 Diffuse Intrinsic Pontine Glioma line	Buczkwicz et al., 2014	N/A
See Table S1 for more detailed information of all cell lines used in this study		N/A
Experimental models: Organisms/strains		
Mouse: Athymic Nude Foxn1nu	Charles River Laboratories	Strain 490
Oligonucleotides		
SMPD1 qPCR forward primer: 5'TGCC AGGTTACATCGCATAG3'	This study	N/A
SMPD1 qPCR reverse primer: 5'AGGT TGATGGCGGTGAATAG3'	This study	N/A
SLC6A4 qPCR forward primer: 5'AACA ACTGCTACCAAGATGC3'	This study	N/A
SLC6A4 qPCR reverse primer: 5'CTCA TCTCAGCCATGTAACC3'	This study	N/A
HTR2C qPCR forward primer: 5'GATT ATGTCTGGCCACTACC3'	This study	N/A
HTR2C qPCR reverse primer: 5'GGAA CTGATACACCGATCC3'	This study	N/A

(Continued on next page)

Continued

REAGENT or RESOURCE	SOURCE	IDENTIFIER
SGMS1 qPCR forward primer: 5'TACA CTGTGGACGTGGTGGT3'	This study	N/A
SGMS1 qPCR reverse primer: 5'CAGG AGGTTTCATCTGGGAAG3'	This study	N/A
SGMS2 qPCR forward primer: 5'CAAT TCCTTGCTGCTTCTCC3'	This study	N/A
SGMS2 qPCR reverse primer: 5'CCAA TCTTCTGAACCCGTGA3'	This study	N/A

Recombinant DNA

pLVX-Puro Vector	Clontech	Cat#632159
pLVX-Puro-SMPD1	This study	N/A
PLVX-Puro-AKT-E17A-CA	Bi et al., 2019	N/A
Non-targeting control shRNA	Bi et al., 2019	N/A
SMPD1-1 shRNA, target sequence: CTGGTTTAGCTGGATATGGGA	This study	N/A
SMPD1-2 shRNA, target sequence: CCCACATTTGGGAAAGTTCTT	This study	N/A
SLC6A4-1 shRNA, target sequence: GGACATTTAAAGAGCGTATTA	Sigma	TRCN0000422925
SLC6A4-2 shRNA, target sequence: CAAGGCCTCCAGCCACTTATT	Sigma	TRCN0000423041
HTR2C-1 shRNA, target sequence: CCGTTTCAATTGCGGACTAA	Sigma	TRCN0000009101
HTR2C-2 shRNA, target sequence: CCGCTGACGATTATGGTGATT	Sigma	TRCN0000009102
SGMS1-1 shRNA, target sequence: GCGAAGAATAATGAAGCTCAT	Sigma	TRCN0000134296
SGMS1-2 shRNA, target sequence: CTGTACCTGTATCGGTGTATT	Sigma	TRCN0000422754
SGMS2-1 shRNA, target sequence: GCTGTAACCAAAGGTATAGTT	Sigma	TRCN0000122186
SGMS2-1 shRNA, target sequence: GCTTGTTAAAGAGGTGCCAAA	Sigma	TRCN0000122885

Software and algorithms

Image Lab Software	Bio-Rad	RRID:SCR_014210
GraphPad Prism 8	GraphPad Software	RRID:SCR_002798
ImageJ	NIH	RRID:SCR_003070
FlowJo v10	Treestar	RRID: SCR_008520
Leica LAS software	Leica	RRID:SCR_013673
Visiopharm	Visiopharm	https://visiopharm.com/
GSEA	Subramanian et al., 2005	http://www.gsea-msigdb.org/gsea/index.jsp
cBioPortal	Cerami et al., 2012 ; Gao et al., 2013	https://www.cbioportal.org/
GEPIA	Tang et al., 2017	http://gepia.cancer-pku.cn/
DepMap Portal	Corseello et al., 2020 ; Ghandi et al., 2019	https://depmap.org/portal

RESOURCE AVAILABILITY

Lead contact

Further information and requests for resources and reagents should be directed to and will be fulfilled by the lead contact, Paul S. Mischel (pmischel@stanford.edu).

Materials availability

All unique reagents generated in this study will be available upon request. A materials transfer agreement may be required.

Data and code availability

- All RNA-seq data generated in this study have been deposited at the GEO database (GEO: GSE158674) and are publicly available as of the date of publication. More data of patient analysis in electronic medical records generated in this study have been deposited at Mendeley Data and are publicly available as of the date of publication. Accession numbers or DOIs are listed in the [key resources table](#). Other data reported in this paper will be shared by the lead contact upon request.
- All software and packages applied are publicly available and listed in the [key resources table](#) and methods. This paper does not report original code.
- Any additional information required to reanalyze the data reported in this paper is available from the lead contact upon request.

EXPERIMENTAL MODEL AND SUBJECT DETAILS

Cell lines

Patient-derived GBM neurosphere lines were obtained as previously described ([Buczkwicz et al., 2014](#); [Laks et al., 2016](#); [Nagaraja et al., 2019](#); [Turner et al., 2017](#)) and were cultured in DMEM/F12 medium supplemented with 1x B27, 20 ng/ml of EGF, 20 ng/ml of FGF, 1 μ g/ml heparin and 1x Glutamax (GIBCO). U87EGFRvIII cells were established by stably expressing EGFRvIII in U87 cells, as previously described ([Wang et al., 2006](#)). U87, U87EGFRvIII, RPE1, and IMR90 cells were maintained in DMEM supplemented with 10% FBS and 1% penicillin/streptomycin, while normal human astrocytes (NHA) were cultured according to the manufacturer's standard protocol by using the astrocyte growth medium BulletKit (Lonza). The attached cells were maintained in 10% FBS medium and changed to 1% FBS medium for follow-up experiments as indicated in the methods. All cell lines were maintained at 37°C in a humidified incubator with 5% CO₂. More detailed information for all cell lines used in this study is listed in [Table S1](#).

Intracranial GBM xenograft models

All mice experiments were approved by the Institutional Animal Care and Use Committee (IACUC) at the University of California, San Diego. Intracranial GBM xenograft models were established as described previously ([Bi et al., 2019](#)). In brief, patient-derived neurosphere cells were first engineered to express a near-infrared fluorescent protein IRFP720, and U87EGFRvIII cells were stably expressed with the turboFP635 protein. A total number of 5×10^4 U87EGFRvIII-FP635 cells, or 5×10^4 GBM39-IRFP cells, or 2.5×10^5 HK296-IRFP cells in 5 μ l PBS were intracranially injected into brains of five-week-old female athymic nude mice (Charles River Laboratories). 6~8 mice were injected for each group. For drug treatment, fluoxetine solution stocks were prepared by dissolving fluoxetine in water. Equal volumes of fluoxetine stocks or vehicle (water) were administered to mice once daily (4.2 mg/kg, 10 mg/kg, 15 mg/kg, or 16.4 mg/kg) by oral gavage after tumors were established at day 8~10. DMSO or temozolomide resuspended in DMSO was administered to mice once daily (5 mg/kg or 20 mg/kg) via intraperitoneal injection starting from day 8 for 5 days. For U87EGFRvIII xenograft models, 10 mg/kg fluoxetine or vehicle was administered to mice once daily by oral gavage for 10 days starting from day 8 after tumor cells injection. Tumor growth was assessed using an FMT 2500 fluorescence tomography system (PerkinElmer), and survival dates until the onset of neurologic symptoms were recorded for survival curves. All mice were housed in a conventional barrier facility at 22°C on a 12-hour light/dark cycle with free access to water and food, and their health status was checked by following the protocols.

METHOD DETAILS

Gene expression and shRNA transduction

Lentivirus *SMPD1* expression plasmid was generated by cloning the full-length coding sequence of *SMPD1* into a pLVX-Puro vector (EcoRI and XbaI). Lentivirus shRNA plasmids were purchased from Sigma, and shRNA sequences are listed in the [Key resources table](#). For virus production, lentiviral shRNA or gene expression plasmids were transfected with lentivirus packaging plasmids (Clontech) into HEK293T cells, and the supernatant containing virus was collected at 72 hours after transfection. Virus titers were measured before use, and fresh culture medium was changed to the cells after overnight infection. Infection efficiency and selection concentrations of puromycin were determined for every cell line before the follow-up experiments.

DepMap data analysis

Gene expression, genetic dependency (combined RNAi-screening from Broad, Novartis, and Marcotte projects), and drug sensitivity (PRISM Repurposing Primary Screen 19Q4) datasets ([Corsello et al., 2020](#); [Ghandi et al., 2019](#); [McFarland et al., 2018](#); [Nusinow et al., 2020](#)) of Cancer Cell Line Encyclopedia (CCLE) were downloaded from the DepMap portal (<https://depmap.org/portal>). Mean differences of mRNA expression levels and shRNA dependency scores (DEMETER2) were calculated between glioma cell lines and other CCLE cell lines, and two-tailed Student's t test was performed to test the significance. For drug sensitivity, the cell viability response

to selected compounds (replicate collapsed log fold change values relative to DMSO) of all glioma cell lines from the DepMap dataset was analyzed by Pearson correlation and plotted as a drug-drug sensitivity matrix.

Sphingolipid analysis by LC-MS

GBM cells were treated with DMSO or 5 μ M fluoxetine in 1% FBS DMEM medium for 24 hours or 42 hours and harvested as pellets. Samples were then spiked with a set of internal standards and extracted with an organic solvent system consisting of equal parts of dichloromethane and methanol. Phase separation was achieved by the addition of an equal part of water. The organic layer was collected, the solvent was removed under argon, and the samples were reconstituted in 100 μ l of isopropanol/acetonitrile (40/60, v/v). Sphingolipids were separated by liquid chromatography (LC), and the eluting metabolites were measured by mass spectrometry (MS/MS) according to methodologies established at the UCSD LIPID MAPS Lipidomics Core (<https://www.ucsd-lipidmaps.org>). Briefly, a Waters Acquity UPLC system (Waters Technologies, Milford, MA) with a Phenomenex Kinetex C18 column, 150x2.1 mm, 1.7 μ m (Phenomenex, Torrance, CA) was used for chromatographic separation. Gradient elution started at 40% mobile phase B for 10 minutes, then increased linearly to 100% B over 10 minutes, kept at 100% B for 30 minutes, and the column was equilibrated with 40% B for 8 minutes. Buffer A consisted of 100% H₂O with 10mM ammonium formate and 0.1% formic acid modifiers. Buffer B consisted of isopropanol/acetonitrile (40/60, v/v) with 10mM ammonium formate and 0.1% formic acid as modifiers. The flow rate was 300 μ l/minute, and 10 μ l of sample was injected via autosampler.

The LC eluent was interfaced with a mass spectrometer 6500 QTrap (Sciex, Framingham, MA), controlled by Analyst v. 1.7 software, operated in Information Dependent Acquisition mode (IDA), using an Enhanced MS (EMS) scan from m/z 400-1000 at 10000 Da/s as a survey scan. Source parameters were automatically optimized using flow injection analysis into an isocratic flow of 80% mobile phase B using individual lipid molecules. To maximize metabolite coverage and identification, the sphingolipids were analyzed in positive and negative ion modes. The optimized source parameters of the Turbo V ion source for positive ion mode were as follows: Curtain Gas, 20; Collision Gas, High; IonSpray voltage, 5000; Temperature, 300; Gas 1, 30; Gas 2, 30, Declustering Potential, 100; Collision Energy Spread, 0; Collision Energy, 45. Source parameters for negative ion mode were: Curtain Gas, 20; Collision Gas, High; IonSpray voltage, -4500; Temperature, 300; Gas 1, 30; Gas 2, 30, Declustering Potential, -150; Collision Energy Spread, 0; Collision Energy, -10. From each survey scan, the ions exceeding a pre-set intensity threshold were chosen for Enhanced Product Ion scans (EPI). The lipid molecules were identified by molecular mass, elution time and MS/MS fragmentation patterns. At least three biological replicates were performed for each cell line per treatment. For quantitation, the MS signals of endogenous sphingolipid molecules were normalized to that of the internal standards and the cell numbers of each sample.

Sphingomyelin (d18:1/n16:0-d9) metabolomics

Sphingomyelin (d18:1/16:0-d9) was diluted and mixed with the FBS-free DMEM medium at room temperature for 1 hour before feeding the cell. GBM cells were pre-treated with 5 μ M fluoxetine or DMSO in the FBS-free DMEM medium for 4 hours and then incubated with 2 μ M sphingomyelin (d18:1/16:0-d9) and 5 μ M fluoxetine or DMSO in FBS-free DMEM medium for another 2 hours. After three-times wash with PBS, cells were harvested as pellets and stored at -80°C for further analysis. The total cell metabolome was extracted in 4 mL 2:1:1 CHCl₃/MeOH/DPBS (v/v/v) solution containing 1 nmol each of SM (d18:1/n17:0) and Ceramide (d18:1/n17:0) spiked in as an internal standard. The mixture was vortexed vigorously and centrifuged at 2,000 x g for 5 min at 4°C. The bottom organic phase was collected, and the remaining aqueous phase was re-extracted by the addition of 2 mL CHCl₃. Both of the organic phases were pooled, dried down under N₂ gas, and reconstituted in 150 μ L 2:1 CHCl₃/MeOH (v/v) for LC/MS analysis.

Metabolites analyzed in this study were quantified using LC/MS-based multiple reaction monitoring (MRM) methods (Agilent Technologies 6470 Triple Quad). MS analysis was performed using ESI with the following parameters: drying gas temperature, 350°C; drying gas flow, 9 l/min; nebulizer pressure, 45 Ψ ; sheath gas temperature, 375°C; sheath gas flow, 12 l/min; fragmentor voltage, 85 V; and capillary voltage, 3.5 kV. The MRM transitions for the targeted LC/MS analysis of SM (d18:1/n17:0) and SM (d18:1/n16:0-d9) were the following: 717.9 to 184.4 and 712.9 to 184.4, respectively and the collision energy was set to 30. The separation of metabolites was achieved using a 50 mm x 4.6 mm 5 μ m Gemini C18 column (Phenomenex) coupled to a guard column (Gemini: C18: 4 x 3 mm). The samples were analyzed in positive mode with the following buffer system: buffer A, 100% H₂O with 10 mM Ammonium Acetate and 0.1% Formic acid (v/v) and buffer B, 100% MeOH with 10 mM Ammonium Acetate and 0.1% Formic acid (v/v). The LC gradient was the following after injection: start from 50% A for 1.1 minutes and increased to 80% B at 0.3 mL/min for 1.2 minutes; increase to 100% B at 0.3 mL/min over 8 minutes; maintain 100% B at 0.3 mL/min for 9.6 minutes and then back to 50% A at 0.3 mL/min and equilibrate for 4 minutes. Lipid species were quantified by measuring areas under the curve in comparison to the corresponding internal standards and then normalizing to the cell number.

SMPD1 enzymatic activity assay

The enzymatic activity of acid sphingomyelinase (SMPD1/ASM) was measured by the cleavage of HMU-PC using a commercial kit (Echelon, K-3200) as described previously ([van Diggelen et al., 2005](#)). GBM cells with indicated hours DMSO or fluoxetine treatment were collected. Cell pellets were then resuspended in water with proteinase inhibitor and sonicated in an ice water bath for 10 cycles (30 s on and 30 s off). Tumor samples were first homogenized in water with proteinase inhibitor by a rotor-stator tissue homogenizer and then sonicated on ice. After 5-minutes centrifugation (10,000 x g) at 4°C, protein concentration of each sample was determined. Equal volumes of 10 μ g samples were added into each reaction and incubated at 37°C for 3 hours. After adding the stop buffer, the

fluorescence of HMU was recorded on an Infinite M1000 Plate Reader (Tecan) at 360 nm excitation and 460 nm emission. Data were normalized to that of the indicated control group and plotted from four biological replicates.

Cell viability assay

Cell viability was assessed using a CellTiter-Glo luminescent cell viability assay kit (Promega). Attached cells or GBM neurosphere cells were seeded into each well of 384-well plates with DMEM medium supplemented with 1% FBS and 1% penicillin/streptomycin or DMEM/F12 medium supplemented with 1/4x B27, 20 ng/ml of EGF, 20 ng/ml of FGF, 1 μ g/ml heparin, and 1x Glutamax respectively. Equal volumes of vehicles or drugs diluted with the medium were added into the wells the next day, and the cells were cultured for 72 hours. After 15 minutes of incubation with CellTiter-Glo reagent at room temperature, the luminescent was recorded using an Infinite M1000 Plate Reader (Tecan). Four biological replicates were performed for each cell line per treatment. The area under the curve (AUC) was calculated by the AUC function in the DescTools R package with the “spline” method, which results in the area under the natural cubic spline interpolation.

Cell death and Annexin V-positive cell analysis

Annexin V-positive cells were determined by flow cytometry using a FITC Annexin V Apoptosis Detection Kit (BD Biosciences). In brief, cells were treated with DMSO or fluoxetine and cultured for 72 hours in DMEM medium with 1% FBS (attached cells) or DMEM/F12 medium supplemented with 1/4x B27, 20 ng/ml of EGF, 20 ng/ml of FGF, 1 μ g/ml heparin and 1x Glutamax (neurosphere cells). For shRNA experiments, cells after shRNA lentivirus infection were reseeded and cultured for 72 hours. Cells were then collected for Annexin V/ PI staining and analyzed by using a BD LSRII flow cytometer (BD Biosciences). For cell death trypan blue assay, cells were seeded in 6-well plates (attached cells) or 25 cm² flasks (neurosphere cells) and cultured for five days after shRNA lentivirus infection or with drug treatment. Dead cells and live cells were counted by trypan blue assay using a TC10 automatic cell counter (Bio-Rad). At least three biological replicates were performed for each cell line per treatment.

Soft-agar colony formation assay

For each well of 12-well plates, 4000 HK296 cells or 2000 U87EGFRvIII cells were mixed with 0.4% low-gelling-temperature agarose (Sigma) in growth medium and immediately plated onto a solidified bottom layer containing 1% low-gelling-temperature agarose in the growth medium. Four biological replicates were performed for each treatment, and cells were treated and fed with fresh growth medium every three days for 3 weeks. Colonies were then stained with 0.005% crystal violet, imaged by a ChemiDoc MP imaging system (Bio-Rad), and counted by ImageJ.

Crystal violet clonogenic assay

24 hours after shRNA or gene expression lentivirus infection, 2000 GBM cells were reseeded into each well of 6-well plates and cultured in 2 mL growth medium for 2 weeks. The medium was refreshed every three days and removed before crystal violet staining. Colonies were fixed with 80% methanol in ddH₂O for 10 minutes and stained with 0.05% crystal violet for 20 minutes. After washed with water, plates were imaged on a ChemiDoc MP imaging system (Bio-Rad), and colony density was quantified by ImageJ.

RNA extraction and qRT-PCR

Total RNA extraction was performed using an RNeasy mini kit (QIAGEN) and the SuperScript IV VIL0 master mix (Invitrogen) was used for reverse transcription. Samples are mixed with primers and SYBR Green Supermix and amplified on a CFX96 real-time PCR detection system (Bio-Rad). The results were processed by the $\Delta\Delta C_t$ method, and expression levels were normalized to the reference gene and indicated control group.

Immunofluorescence staining

Cells were seeded in laminin-coated chamber slides and treated with DMSO or 5 μ M fluoxetine for 42 hours. After twice wash with PBS, cells were fixed in 4% PFA for 15 minutes, permeabilized with 0.2% Triton X-100 in PBS for 15 minutes and then blocked with 2% BSA in PBS for 45 minutes. Primary antibodies (anti-LAMP1, #9091, Cell Signaling at 1:200 dilution; anti-phospho-histone H2A.X (Ser139), 05-636, Millipore at 1:200 dilution) in PBS with 0.02% Triton X-100 and 0.5% BSA was applied to cells and incubated overnight at 4°C. After four washes with PBS, cells were then incubated with fluorescent secondary antibody Alexa Fluor anti-Rabbit 546 (A11010, Invitrogen) or Alexa Fluor anti-Mouse 488 (A11017, Invitrogen) at a dilution of 1:1000 in PBS at room temperature for 1 hour. For EGFR staining, an EGFR antibody conjugated with Alexa Fluor 488 (#5616, Cell Signaling) was used at 1:200 dilution in overnight incubation. For LysoTracker staining, after 42 hours treatment of DMSO or 5 μ M fluoxetine, cells were washed with PBS and incubated with 50 nM LysoTracker (L7528, Invitrogen) at 37°C for 1 hour. Cells were then washed with PBS, fixed in 4% PFA for 15 minutes. After four washes with PBS, cells were mounted with antifade reagent with DAPI (Life Technologies) for imaging on an Olympus FV1000 confocal microscope. Fluorescent intensity was quantified by ImageJ.

Drug and lipid treatment

For western blot, cells were collected after 48 hours of treatment unless otherwise indicated. GBM neurosphere cells were seeded in DMEM/F12 medium supplemented with 1/4x B27, 20 ng/ml of EGF, 20 ng/ml of FGF, 1 μ g/ml heparin, and 1x Glutamax, cultured

overnight, and treated with DMSO or fluoxetine for indicated hours before harvesting for enzymatic assay or western blots. In proteasome and lysosome inhibitors experiments, GBM cells were treated with DMSO or fluoxetine for 24 hours and incubated for additional 6 hours in the absence or presence of 10 μ M MG132 or 50 μ M Chloroquine before collecting. For lipid treatment, 10 μ M of sphingolipids conjugated with BSA or an equal amount of BSA solution was added into the growth medium and mixed on a shaker at room temperature for 30 minutes before treating cells. Cells were then cultured with the lipid or vehicle-adding medium for 48 hours and applied for further western blot analysis or immunofluorescence staining. In cell viability assay, GBM cells were first cultured with lipid or vehicle-adding medium overnight and then incubated together with fluoxetine or DMSO for 72 hours before CellTiter-Glo assay.

Membrane lipid order imaging of live cells

Membrane lipid order imaging of live GBM cells was performed as described previously (Owen et al., 2011). Briefly, GBM cells in glass-bottom dishes were treated with 5 μ M fluoxetine for 40 hours in 1% FBS DMEM medium and then stained with 5 μ M Laurdan (D250, Invitrogen) for 3 hours in serum-free medium at 37°C in a humidified incubator with 5% CO₂. Cells were then imaged on a Leica SP5 Confocal/Multiphoton system with the excitation at 800 nm and the emission at 400–460 nm and 470–530 nm). Pseudo-colored generalized polarization (GP) images were achieved by using an ImageJ plug-in as described (Owen et al., 2011). GP values at the plasma membrane region of at least 60 cells were quantified by ImageJ and plotted as histograms.

Western blot analysis

Cells were washed with cold PBS and lysed with 1x RIPA lysis buffer containing 1x protease and phosphatase inhibitor cocktail on ice for 30 minutes. Tumor samples were homogenized on ice with cold PBS supplemented with protease and phosphatase inhibitor cocktail and then lysed with an equal volume of 2x RIPA buffer on ice for 30 minutes. BCA protein assay kit (Thermo Scientific) was used to determine the protein concentration. Equal amounts of protein samples were mixed with Laemmli sample buffer, boiled at 100°C for 5 minutes, electrophoresed using 4%–12% NuPAGE Bis-Tris mini gels, and then transferred onto nitrocellulose membranes by a Trans-Blot Turbo transfer system (Bio-Rad). Membranes were blocked with 5% BSA in TBST buffer and incubated with corresponding primary antibodies at 4°C overnight, followed by incubation with HRP-conjugated secondary antibodies at room temperature for 1 hour. After washing, the blots were developed with SuperSignal West Pico chemiluminescent substrate (Thermo Scientific) and imaged using Image Lab software on a ChemiDoc MP imaging system (Bio-Rad).

Immunohistochemistry analysis

Formalin-fixed, paraffin-embedded tissue sections were performed by the Tissue Technology Shared Resource (TTSR)-Histology Core at UCSD. Standard staining protocols were followed. In brief, the antigen was retrieved by boiling slides in 0.01 M sodium citrate (pH 6.0) for 15 minutes. Tissue sections were then incubated with primary antibodies overnight at 4°C, followed with 30 minutes incubation with biotinylated secondary antibodies at room temperature. Tissue sections for TUNEL staining were incubated with TdT/ dUTP at 37°C for 30 minutes and then with HRP-conjugated anti-digoxigenin at room temperature for another 30 minutes. Stained slides were imaged on an Olympus BX43 microscope and quantified in a double-blind fashion using Visiopharm image analysis software.

Cell surface EGFR and internalization analysis

The intensity of cell surface EGFR was determined by flow cytometry with an EGFR antibody that recognizes the extracellular domains of both wild-type EGFR and EGFRvIII proteins as described previously (Lu et al., 2007; Luwor et al., 2001). In brief, GBM39 and HK296 cells were first chilled on ice for 20 minutes and then incubated with a primary EGFR antibody (GR01, Millipore, mAb528, 1:20) on ice for one hour. After gently washed once with 10 mL cold PBS, the cells were incubated with an Alexa Fluor 488 goat anti-mouse second antibody (A11017, Invitrogen, 1:500) on ice for an additional hour. The cells were then gently washed once with 10 mL cold PBS and analyzed on a BD LSRFortessa X-20 flow cytometer (BD Biosciences). For EGFR internalization assay, GBM39 cells treated with 5 μ M fluoxetine or DMSO for 48 hours were chilled on ice and incubated with the EGFR antibody (GR01, Millipore, mAb528, 1:40) on ice for one hour. Primary antibody-stained cells were either kept on ice or moved to 37°C for 15 or 30 minutes to allow internalization. Following internalization, the cells were washed and incubated with Alexa Fluor 488 goat anti-mouse second antibody (Cat#A11017, Invitrogen, 1:500) for another hour before analyzing by flow cytometer. Internalized EGFR level was defined as the decreased signal of surface EGFR after incubation at 37°C. Three to four biological replicates were performed for each treatment. A total of 10, 000 events for each sample was recorded and analyzed.

Density gradient fractionation

The detergent-free density gradient fractionation was performed as previously described (Cizmecioglu et al., 2016; Macdonald and Pike, 2005). In brief, GBM39 cells treated with 5 μ M fluoxetine or DMSO for 48 hours were pelleted at 250 g for 5 minutes, washed once with cold PBS, and resuspended in 1 mL of cold homogenization buffer (20 mM Tris-HCl, pH7.8, 0.250 M sucrose, 1 mM CaCl₂ and 1 mM MgCl₂) with protease and phosphatase inhibitors. Homogenates were then passed through a 23 g needle for 20 times followed by centrifugation at 4°C at 1000 g for 10 min. 1 mL of supernatants were collected, mixed with 1 mL of 50% Opti-Prep solution (Sigma), and placed in the bottom of a 5 ml Ultra-Clear centrifuge tube (Beckman Coulter). 400 μ l each of 20%, 17.5%, 15%,

12.5%, 10%, 7.5% and 5% Opti-Prep solutions were then poured onto the top. After ultracentrifugation at 100,000 g for 2 hours at 4°C using an SW-55Ti rotor in a Beckman ultracentrifuge, equal volumes of six fractions were collected from the top layer to bottom layer and loaded for further western blot analysis. Lipid rafts fractions were characterized by the non-lipid rafts marker Calnexin and lipid rafts markers Flotillin-1 and G α (q). The percentages of protein level in fraction 1 were calculated by dividing the amount of protein in fraction 1 by the total amount of protein in all six fractions and plotted from three independent experiments.

RNA-seq analysis

Neurosphere cells were treated with DMSO or 5 μ M fluoxetine for 42 hours and collected for RNA extraction. RNA sequencing was performed by Novogene. RNA-Seq reads were aligned to the human reference transcriptome (GRCh38 release-98) and quantified using the Salmon software (Patro et al., 2017). The `-gcBias` flag was used to estimate a correction factor for systematic biases commonly present in RNA-seq data. The differential expression analysis was performed using the likelihood ratio test (LRT) in DESeq2 (version 1.32.0) (Love et al., 2014). The LRT examines two nested models for the read counts, a full model where gene expression was explained by fluoxetine treatment and cell lines and a reduced model, in which only cell lines were considered. The test determines if fluoxetine treatment contributed significantly to the gene expression beyond the expected expression level due to cell lines. Gene Set Enrichment Analysis (GSEA) was performed on all genes ranked by likelihood ratio test statistic against MSigDB v7.1 (Subramanian et al., 2005). Enriched terms, including EGFR signaling inhibitor down and up signatures (Kobayashi et al., 2006) (https://www.gsea-msigdb.org/gsea/msigdb/cards/KOBAYASHI_EGFR_SIGNALING_24HR_DN and https://www.gsea-msigdb.org/gsea/msigdb/geneset_page.jsp?geneSetName=KOBAYASHI_EGFR_SIGNALING_24HR_UP), were visualized using ClueGO (Bindea et al., 2009).

TCGA data analysis

TCGA GBM datasets were downloaded from Broad GDAC Firehose and matched for the following analysis. In survival association group analysis, we used the “lifelines” package in python to fit Cox proportional hazard models (Andersen and Gill, 1982). *P* values were calculated by log likelihood ratio tests. To evaluate whether a gene’s expression provides additional prognostic information beyond the baseline survival probability due to age at diagnosis, we compared the likelihood of two nested models: a full model with gene expression and age of patients and a reduced model, in which only age was considered. Proportional hazards model and log-rank test were applied to assess the prognostic significance of individual genes. Overall survival of patients with the top 25% and bottom 25% of *SMPD1* expression in the TCGA GBM cohort (RNA-seq) was statistically compared by Log-rank test. Cox proportional hazard ratios were calculated. *P* values and numbers of patients of each cohort were indicated in the figure. The Gene Expression Profiling Interactive Analysis (GEPIA) web-server (Tang et al., 2017) was used to analyze the expression of metabolic genes between GBM tumors and normal brains based on TCGA and GTEx RNA-seq data. The genetic alterations of *EGFR*, *SMPD1*, and *IDH1* in the merged cohort of LGG and GBM TCGA (PanCancer Atlas) datasets were assessed using cBioPortal for Cancer Genomics (<https://www.cbioportal.org/>) (Cerami et al., 2012; Gao et al., 2013). Gene set enrichment analysis was performed to characterize genes differentially expressed in GBM clinical samples (TCGA GBM, HGU133A) with high or low *SMPD1* expression. The median of the GBM cohort was chosen as the cutoff for high and low *SMPD1* expression groups.

Patient survival in Electronic Medical Records

The ICD-9 and ICD-10 codes were used to initially identify subjects with brain cancer diagnosis in the IBM Health MarketScan database (2003-2017) (IBM Watson Health, 2018). Records of temozolomide prescription, radiation therapy, and surgical resection of tumor were used to enrich the final cohort for patients with GBM. More specifically, we used NDCs to query patient claims history for medications most frequently used for GBM treatment with or without depression symptoms: temozolomide (217 NDC codes), chemotherapy (2,110 NDCs), fluoxetine (910 NDCs), citalopram (692 NDCs), and escitalopram (338 NDCs). In addition, we used CPT codes J8700 and J9328 representing oral administration of temozolomide. To ascertain radiation therapy, we used CPT code range 77261-77799, and radiation therapy services HCPCS codes in range G6001 to G6017. For detecting surgical resection of brain tumor, we used CPT codes relevant to craniectomy or craniotomy procedures for surgical resection of brain tumor (codes 61510, 61516, 61518, 61520, 61521, 61524, 61526, 61530, 61534, 61536, 61544, and 61545). For detecting chemotherapy treatment, we used CPT codes representing “chemotherapy administration and other highly complex drug or highly complex biologic agent administration” in range 96401-96549; chemotherapy drugs HCPCS code range J9000-J9999, and codes for chemotherapy administration with intravenous infusion and other than infusion technique, G0498, Q0083, Q0084, and Q0085. To further detect anti-neoplastic therapies (radiation therapy, chemotherapy, immunotherapy, or their combinations), we used ICD-9 codes: V58.0, V58.1, V58.11, V58.12, V66.1, V66.2, V67.1, V67.2, and ICD-10 codes: Z51.0, Z51.1, Z51.11, Z51.12, and Z08. For identifying brain cancer diagnoses, we used ICD-9 codes ‘191.x’ and ICD-10 codes ‘C71.x’. For identifying all other cancer diagnoses, we used the entire ICD sub-classification of malignant neoplasms (ICD-9 range 140-209 and ICD-10 code range C00-C96) excluding codes for malignant neoplasm of brain.

For each patient with GBM, we computed the number of days from index GBM diagnosis to the day the patient died in a hospital. To adjust results for the *immortal time bias* (Lévesque et al., 2010; Suissa, 2007), SSRI antidepressant exposure was computed as a time interval-dependent value (Zhou et al., 2005). The start date of the SSRI antidepressant exposure was the date of first SSRI antidepressant prescription dispensed after index GBM diagnosis. To limit potential bias due to the difference in probabilities of

receiving SSRI treatment, we matched each SSRI treated patient to two non-SSRI treated patients based on pre-treatment covariates to improve the balance between treated and non-treated covariate distributions. The propensity-score matching was performed as a nonparametric preprocessing step for reducing model confounding in parametric causal inference. Matching was done on three covariates (age, sex, and the Elixhauser comorbidity index score) using the method implemented in the R “Matchit” package (version 3.0.2).

The Kaplan-Meier (KM) method (Kaplan and Meier, 1958) was performed to estimate the survival function for patients treated with one of the three SSRI antidepressants against those with standard GBM treatment but no SSRI antidepressant exposure. Further, an extended Cox proportional hazard regression model with time-dependent variable (Andersen and Gill, 1982; Therneau and Grambsch, 2000) was used to assess the variation in hazards associated with three SSRI antidepressants exposure. Separate experiments for each SSRI antidepressant were conducted to estimate the hazards ratio (HR) of all-cause death among the patients with GBM. Multiple observations from the same patient were indicated by the patient-level identifier in the mode to compute a robust (cluster) variance for the model. The validity of proportional hazards assumption was evaluated using Schoenfeld test (Grambsch and Therneau, 1994; Schoenfeld, 1980) performed on individual predictors and the over model. Cox PH regression was achieved in R (version 3.6.3), using “survival” package (Therneau and Lumley, 2015) (version 3.2-3) and “coxph” function with time dependent exposure modeling. The survival curves were produced using “survminer” R package (version 0.4.8.999). The Elixhauser comorbidity index was computed using R ‘icd’ package (version 4.0.9) and ‘comorbidity’ package (version 0.5.3). More details of the data overview, data extraction pipeline, exclusion criteria, enrichment for patients with GBM, statistical analyses, and results are available in Mendeley Data: <https://doi.org/10.17632/5gww3pgbj3.1>.

QUANTIFICATION AND STATISTICAL ANALYSIS

Unless otherwise indicated, all statistical analysis was performed using GraphPad Prism 8 software. Unpaired two-tailed Student’s t test with equal variances assumed was applied to compare two experimental groups, and one-way or two-way ANOVA followed by multiple comparisons test was used to assess differences between three or more experimental groups. Paired two-tailed Student’s t test was only performed in comparing the percentage of protein intensity in paired samples. Log-rank (Mantel-Cox) test was used in survival analysis. Fisher’s exact test was applied for mutual exclusivity analysis of genetic alterations in TCGA clinical samples and tumor recurrence analysis of PDX mice models. Bar graphs show mean \pm SD or SEM as indicated in the legends, and p values less than 0.05 are defined to be significant. Numbers of samples, statistical tests, and p values analyzed in each experiment are reported in the respective figure legends or methods.

Supplemental information

**Targeting glioblastoma signaling and metabolism
with a re-purposed brain-penetrant drug**

Junfeng Bi, Atif Khan, Jun Tang, Aaron M. Armando, Sihan Wu, Wei Zhang, Ryan C. Gimple, Alex Reed, Hui Jing, Tomoyuki Koga, Ivy Tsz-Lo Wong, Yuchao Gu, Shunichiro Miki, Huijun Yang, Briana Prager, Ellis J. Curtis, Derek A. Wainwright, Frank B. Furnari, Jeremy N. Rich, Timothy F. Cloughesy, Harley I. Kornblum, Oswald Quehenberger, Andrey Rzhetsky, Benjamin F. Cravatt, and Paul S. Mischel

Figure S1




Figure S1. GBMs Are Highly Dependent on Sphingolipid Metabolism, Related to Figure 1

(A) Schematic pathways of sphingolipid metabolism.

(B) 14 coding genes of key enzymes in the sphingolipid metabolism pathway are highly expressed in GBM tumors (TCGA) in comparing with normal brains (GTEX).

(C) Heatmap of gene expression in the merged cohort of low-grade glioma and glioblastoma of TCGA datasets.

(D) Outline of the strategy utilized for identifying metabolic dependency of GBM in the sphingolipid pathway.

(E) Gene dependency analysis of 14 upregulated genes (B) in the sphingolipid metabolism pathway from the DepMap dataset. Glioma cells show a much more significant dependency on *SMPD1* than other sphingolipid metabolic genes.

(F) Rank of genes with the association (hazard ratio) between mRNA expression and overall survival of GBM patients from the TCGA dataset. High *SMPD1* expression is significantly correlated with poor overall survival of GBM patients.

(G and H) Kaplan-Meier analysis of overall survival in GBM patients with high (top 25%) or low (bottom 25%) *SMPD1* mRNA expression in the TCGA HGU133A GBM and Gravendeel GBM cohorts.

Two-tailed Student's t-test for (B) and (E). Log-rank test for (G) and (H). The median value (center line), the min and max (whiskers), and the 25th and 75th percentiles (box perimeters) are presented in (B).

Figure S2




Figure S2. Fluoxetine Selectively Kills GBM Cells through SMPD1 Inhibition, Related to Figure 1 and 2
 (A) Relative cell viability of normal human astrocytes (NHA), U87, and U87 cells expressing *EGFRVIII* treated by fluoxetine (n= 4).
 (B and C) Colony formation of U87EGFRVIII cells in soft agar (n= 4).
 (D) Representative images of NHA and GBM spheres after DMSO or fluoxetine treatment. Scale bar, 500 μ m.
 (E) Representative flow cytometry analysis of Propidium iodide (PI) and Annexin V positive cells after DMSO or fluoxetine treatment.
 (F) Relative mRNA level of *SMPD1* with its overexpression in (E).
 (G) shRNA knockdown efficiency of *SMPD1*, *SLC6A4*, and *HTR2C* in U87EGFRVIII cells.
 (H) mRNA level (RSEM) in GBM patient samples (TCGA).
 (I) Rank of genes with the association (hazard ratio) between mRNA expression and overall survival of GBM patients from the TCGA dataset.
 (J and K) Lipidomic analysis of U87 cells with or without EGFRVIII expression (n= 3).

(L-N) Relative cell viability in NHA and GBM cells (L) and colony formation in soft agar in U87EGFRvIII cells (M and N) treated with myriocin, an inhibitor of sphingolipid *de novo* synthesis.

(O and P) Crystal violet staining for U87 cells expressing EGFRvIII (n= 4).

(Q) Percentage of cell death of U87 cells with or without *EGFRvIII* overexpression after *SMPD1* or non-targeting shRNA transfection (n= 3).

(R) Relative mRNA level of *SMPD1* in three patient-derived GBM lines with indicated shRNA transfection.

For (F), a two-tailed Student's t-test was performed. ANOVA followed by Tukey's multiple comparisons test was applied in (C), (G), (H), (N), and (P-R). Data represent mean \pm SD except (H). The median value (center line) and the 25th and 75th percentiles (dash lines) are presented in (H). **p < 0.01; ***p < 0.001.

Figure S3




Figure S3. Fluxetine-Induced Transcriptional Signatures in GBM Cells, Related to Figure 2

(A) Schematic overview of RNA-seq analysis in 3 GBM neurosphere lines with 42 hours DMSO or fluxetine treatment. Two biological replicates per treatment were performed for each cell line.

(B) Heatmap of differentially expressed genes (FDR < 0.05) between fluxetine and DMSO treatment in GBM39, HK296, and HK301 cells.

(C) Selected most significantly upregulated or downregulated transcriptional signatures by GSEA. FDR q-value and NES are shown.

(D) Gene Ontology (GO) enrichment analysis showing both upregulated and downregulated transcriptional signature clusters.

(E) *EGFR* and *SMPD1* mRNA level in GBM clinical samples of TCGA GBM (HUG133A) cohort.

(F) Volcano plot of differentially expressed genes in TCGA GBM clinical samples (HUG133A) with high or low *SMPD1* expression. RTKs genes are labeled as red.

(G) Genetic alterations of *EGFR*, *SMPD1*, and *IDH1* in merged LGG and GBM cohort of TCGA pan-cancer dataset (1106 samples). Deep deletion of *SMPD1* is mutually exclusively associated with *EGFR* amplification and gain of function mutations in clinical tumor samples.

(H) Kaplan-Meier analysis of overall survival in the wild-type IDH1 GBM patients with high or low *SMPD1* mRNA expression in EGFR amplification/ gain cohort of TCGA RNAseq dataset. The cutoff for high and low *SMPD1* expression cohorts is 10.60.

(I) Kaplan-Meier analysis of overall survival in wild-type IDH1 GBM patients with high (top 25%) or low *SMPD1* (bottom 75%) mRNA expression in the classic-like cohort of TCGA RNAseq dataset.

For (E), the median value (center line), the min and max (whiskers), and the 25th and 75th percentiles (box perimeters) are presented. ANOVA followed by Tukey's multiple comparisons test for (E), two-tailed Student's t-test for (F), Fisher's exact test for (G), and Log-rank test for (H) and (I). * $p < 0.05$; ** $p < 0.01$; **** $p < 0.0001$.

Figure S4




Figure S4. Fluoxetine Acts as an Indirect Inhibitor of EGFRvIII by Blocking SMPD1 and Elevating Sphingomyelin Levels, Related to Figure 2

(A) Western blot analysis of EGFR signaling activity in GBM cells expressing non-targeting (NT) or *SMPD1* shRNA.
 (B) Western blot analysis of EGFR signaling activity in normal human astrocytes (NHA) and GBM cells after 48 hours of fluoxetine treatment.
 (C) Western blot showing EGFR and downstream signaling in U87EGFRvIII cells with indicated treatment and gene expression.
 (D) Western blot analysis of EGFR signaling activity in HK385 and HK254 cells after 24 hours of fluoxetine treatment.
 (E and F) AKT signaling and percentage of cell death in GBM39 cells expressed vector or a constitutively active AKT E17A-CA allele (n= 4).
 (G) Western blot showing PDGFRA and downstream signaling in TS576 cells with indicated treatment or shRNA expression.
 (H) Western blot analysis of EGFR, FGFR1, and MET activity in GBM39 cells with 24 hours of indicated treatment.
 (I) Western blot analysis of EGFR signaling activity in GBM39 cells treated with DMSO or 5 μ M fluoxetine for indicated hours.
 (J-L) Sphingomyelin profiles identified by mass spectrometry in U87EGFRvIII cells with 42 hours of DMSO or fluoxetine treatment (n=5).
 (M) LysoTracker staining in GBM39 and HK296 cells. LysoTracker, red; DAPI, blue. Scale bar, 20 μ m.
 (N) Quantification of LAMP1 intensity in GBM39 and HK296 cells (n= 50).
 Data represent mean \pm SD in (F), (K), and (L). The median value (center line), the min and max (whiskers), and the 25th and 75th percentiles (box perimeters) are presented in (N). Two-tailed Student's t-test for (K), (L), and (N). ANOVA followed by Tukey's multiple comparisons test for (F). *p < 0.05; **p < 0.01; ***p < 0.001.

Figure S5




Figure S5. Fluoxetine Kills GBM Cells by Inhibiting SMPD1 and Abrogating EGFRvIII Signaling, Related to Figure 3

(A) Western blot analysis of EGFR protein in GBM39 and HK296 cells with indicated treatment and further incubated for additional 6 hours in the absence or presence of MG132.

(B and C) Western blot analysis of EGFR protein in U87EGFRvIII cells with indicated treatment and further incubated for additional 6 hours in the absence or presence of MG132 or Chloroquine (CQ).

(D and E) Relative *EGFR* mRNA level in GBM cells with 48 hours of fluoxetine treatments (n = 3).

(F-I) Adding sphingomyelins, but not ceramides, suppresses EGFR signaling (F and G) and further decreases cell viability (H and I) in GBM cells (n = 4).

(J) Schematic pathway of roles of SMPD1 and SGMS1/2 in regulating sphingomyelin homeostasis.

(K and L) mRNA expression of *SGMS1* and *SGMS2* in indicated cohorts of TCGA GBM (RNAseq) dataset.

(M) Knockdown efficiency of *SGMS1* and *SGMS2* shRNAs in U87EGFRvIII cells (n= 4).

(N-P) Relative number of live cells (N), percentage of cell death (O), and EGFR activity (P) in U87EGFRvIII cells with indicated treatments and shRNA expression (n= 6).

Data represent mean \pm SD except (K) and (L). The median value (center line), the min and max (whiskers), and the 25th and 75th percentiles (box perimeters) are presented in (K) and (L). Two-tailed Student's t-test for (D) and (K). ANOVA followed by Tukey's multiple comparisons test for (E), (H), (I), and (L-O). *p < 0.05; **p < 0.01; ***p < 0.0001; NS, not significant.

Figure S6




Figure S6. Fluoxetine Suppresses Tumor Growth in Patient-Derived Orthotopic GBM Models, Related to Figure 4

(A) FDA-approved doses of fluoxetine for human non-cancer indications and converted mice doses based on body surface area.

(B) Representative tumor images of GBM39 patient-derived orthotopic mice models. Scale bar, 5 mm.

(C) Body weights of mice bearing patient-derived GBM39 xenograft models with indicated administrations (n= 6 per group). Data represent mean± SD.

(D) Representative images of immunohistochemistry analysis of TUNEL and Ki67 in HK296 xenograft tumors and surrounding mice brains. Scale bar, 100 μm.

(E and F) Immunohistochemistry analysis of LAMP1 in HK296 xenograft tumors and surrounding mice brains by using an antibody that could detect both human and mice LAMP1 proteins (n= 7). Scale bar, 100 μm. Data represent mean± SEM.

ANOVA followed by Tukey's multiple comparisons test in (C) and (F). NS, not significant.

Figure S7




Figure S7. Combination of Fluoxetine and Temozolomide Induces DNA Damage and Suppresses GBM Tumor Recurrence, Related to Figure 5 and 6

(A and B) Downregulated DNA repair pathways in three patient-derived GBM neurosphere lines after fluoxetine treatment.

(C-E) γ H2AX staining analysis of GBM cells. Data are from four replicate samples for each treatment. 2.5 μ M for fluoxetine, and 50 μ M for TMZ. Scale bar, 10 μ m.

(F-H) Representative images (F), relative number of live cells (G), and percentage of cell death (H) of three GBM neurosphere lines after indicated treatment (n= 4). Scale bar, 500 μ m.

(I and J) Colony formation of HK296 cells with indicated treatment in soft agar (n= 4). 2.5 μ M for fluoxetine, and 50 μ M for TMZ.

(K and L) Tumor images of mice with the combination treatment of fluoxetine and TMZ at day 80 or day 160 in GBM39 xenograft models. No tumor signal was identified in 2 mice of low dose TMZ (5 mg/kg) combination group and 6 mice of high dose TMZ (20 mg/kg) combination group. Arrowheads indicate the injection sites of tumor cells. Scale bar, 5 mm.

(M) H&E staining of brain sections in (L) from mice bearing GBM39 xenograft tumors after indicated drug administration. Tumor regions are labeled by dashed lines. Scale bar, 1 mm.

(N) Schematic model of the fluoxetine's anti-GBM effect through SMPD1 inhibition. GBMs are highly dependent on SMPD1 for survival, which is enhanced in *EGFRvIII*-amplified tumors. Fluoxetine kills GBM cells by indirectly inhibiting EGFRvIII by elevating sphingomyelin levels to alter plasma membrane organization, and by causing lysosomal stress. Fluoxetine can be combined with temozolomide to suppress tumor recurrence, as detected in preclinical *in vivo* models and in electronic medical record data from patients.

Data represent mean \pm SD. ANOVA followed by Tukey's multiple comparisons test in (D), (E), (G), (H), and (J). *p < 0.05; ***p < 0.001; NS, not significant.

Table S2. List of ICD-9 and ICD-10 Codes Used to Define Initial Brain Cancer Cohort, Related to Figure 6.

ICD Code	ICD Version	Description
191	ICD-9	Malignant neoplasm of brain
1910	ICD-9	Malignant neoplasm of cerebrum, except lobes and ventricles
1911	ICD-9	Malignant neoplasm of frontal lobe
1912	ICD-9	Malignant neoplasm of temporal lobe
1913	ICD-9	Malignant neoplasm of parietal lobe
1914	ICD-9	Malignant neoplasm of occipital lobe
1915	ICD-9	Malignant neoplasm of ventricles
1916	ICD-9	Malignant neoplasm of cerebellum nos
1917	ICD-9	Malignant neoplasm of brain stem
1918	ICD-9	Malignant neoplasm of other parts of brain
1919	ICD-9	Malignant neoplasm of brain, unspecified
C71	ICD-10	Malignant neoplasm of brain
C710	ICD-10	Malignant neoplasm of cerebrum, except lobes and ventricles
C711	ICD-10	Malignant neoplasm of frontal lobe
C712	ICD-10	Malignant neoplasm of temporal lobe
C713	ICD-10	Malignant neoplasm of parietal lobe
C714	ICD-10	Malignant neoplasm of occipital lobe
C715	ICD-10	Malignant neoplasm of cerebral ventricle
C716	ICD-10	Malignant neoplasm of cerebellum
C717	ICD-10	Malignant neoplasm of brain stem
C718	ICD-10	Malignant neoplasm of overlapping sites of brain
C719	ICD-10	Malignant neoplasm of brain, unspecified

Table S3. Baseline Characteristics of The GBM Enriched Cohort, Related to Figure 6.

	No SSRI (N=182)	Any SSRI (N=56)	Fluoxetine (N=10)	Citalopram (N=13)	Escitalopram (N=38)	All Patients (N=238)
Age						
Mean (SD)	54.3 (10.2)	52.4 (11.8)	54.9 (8.60)	45.8 (11.8)	53.4 (12.5)	53.9 (10.6)
Median [Min, Max]	56 [23, 80]	56 [24, 80]	57 [42, 71]	45 [28, 63]	57 [24, 80]	56 [23, 80]
Age group						
18-40	16 (8.8%)	10 (17.9%)	0 (0%)	5 (38.5%)	7 (18.4%)	26 (10.9%)
41-60	114 (62.6%)	31 (55.4%)	8 (80%)	7 (53.8%)	18 (47.4%)	145 (60.9%)
above 60	52 (28.6%)	15 (26.8%)	2 (20%)	1 (7.7%)	13 (34.2%)	67 (28.2%)
Sex						
Female	70 (38.5%)	30 (53.6%)	9 (90%)	6 (46.2%)	19 (50%)	100 (42%)
Male	112 (61.5%)	26 (46.4%)	1 (10%)	7 (53.8%)	19 (50%)	138 (58%)
Baseline (pre-GBM) follow-up days						
Mean (SD)	1090 (844)	1000 (791)	930 (883)	1280 (912)	843 (695)	1070 (831)
Median [Min, Max]	883 [90, 3720]	889 [96, 3480]	726 [96, 2770]	1120 [227, 3300]	802 [96, 3480]	883 [90, 3720]
Charlson comorbidity score*						
Mean (SD)	0.511 (0.785)	0.357 (0.554)	0.400 (0.516)	0.308 (0.480)	0.368 (0.589)	0.475 (0.739)
Median [Min, Max]	0 [0, 4.0]	0 [0, 2.0]	0 [0, 1.0]	0 [0, 1.0]	0 [0, 2.0]	0 [0, 4.0]
Charlson comorbidity index*						
0	115 (63.2%)	38 (67.9%)	6 (60.0%)	9 (69.2%)	26 (68.4%)	153 (64.3%)
1-2	64 (35.2%)	18 (32.1%)	4 (40.0%)	4 (30.8%)	12 (31.6%)	82 (34.5%)
3-4	3 (1.6%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	3 (1.3%)
>=5	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)
Elixhauser comorbidity score*						
Mean (SD)	1.26 (1.51)	1.14 (1.21)	1.10 (1.37)	0.923 (1.32)	1.16 (1.13)	1.24 (1.44)
Median [Min, Max]	1.0 [0, 7.00]	1.0 [0, 4.00]	0.5 [0, 4.0]	0 [0, 4.0]	1.0 [0, 4.0]	1.0 [0, 7.0]
Elixhauser comorbidity index*						
<0	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)
0	74 (40.7%)	22 (39.3%)	5 (50.0%)	7 (53.8%)	13 (34.2%)	96 (40.3%)
1-4	98 (53.8%)	34 (60.7%)	5 (50.0%)	6 (46.2%)	25 (65.8%)	132 (55.5%)
>=5	10 (5.5%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	10 (4.2%)

*For each patient, the Charlson and the Elixhauser comorbidity indices were computed using ICD codes from their diagnostic history up to six months prior to the index GBM diagnosis.

Table S4. Baseline Characteristics of The Propensity Score-matched GBM Enriched Cohort, Related to Figure 6.

	Fluoxetine		Citalopram		Escitalopram	
	Treated (N=10)	Non treated (N=20)	Treated (N=13)	Non treated (N=26)	Treated (N=38)	Non treated (N=76)
Age						
Mean (SD)	54.9 (8.6)	54.8 (10.9)	45.8 (11.8)	46.1 (12.1)	53.4 (12.5)	53.8 (10.4)
Median [Min, Max]	57 [42, 71]	58 [24, 68]	45 [28, 63]	46 [28, 64]	57.5 [24, 80]	56 [28, 78]
Sex						
Female	9 (90%)	18 (90%)	6 (46.2%)	10 (38.5%)	19 (50%)	38 (50%)
Male	1 (10%)	2 (10%)	7 (53.8%)	16 (61.5%)	19 (50%)	38 (50%)
Elixhauser comorbidity score*						
Mean (SD)	1.10 (1.07)	1.10 (1.37)	0.923 (1.32)	0.962 (1.18)	1.16 (1.13)	1.18 (1.23)
Median [Min, Max]	1 [0, 3]	0.5 [0, 4.0]	0 [0, 4.0]	1 [0, 4.0]	1 [0, 4.0]	1 [0, 4.0]
Elixhauser comorbidity index*						
<0	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)
0	5 (50%)	7 (35%)	7 (53.8%)	12 (46.2%)	13 (34.2%)	31 (40.8%)
1-4	5 (50%)	13 (65%)	6 (46.2%)	14 (53.8%)	25 (65.8%)	45 (59.2%)
>=5	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)

*For each patient, Charlson and Elixhauser comorbidity indices were computed using ICD codes from their diagnostic histories up to six months prior to the index GBM diagnosis. The propensity score matching was performed using R "Matchit" package (version 3.0.2) based on age, sex, and Elixhauser comorbidity score by matching two non-exposed subjects (GBM patients not treated with SSRI) against each exposed subject (SSRI treated GBM patient).

Table S5. Cox Proportional Hazards Regression Results for All-cause In-patient Mortality after Adjusting for Age, Sex, Elixhauser Comorbidity Index Score, and Using Time-dependent SSRI Exposures, Related to Figure 6.

Characteristic	Fluoxetine			Citalopram			Escitalopram		
	HR ¹	95% CI ¹	p-value	HR ¹	95% CI ¹	p-value	HR ¹	95% CI ¹	p-value
Age	1.03	1.01, 1.05	<0.001	1.03	1.01, 1.05	<0.001	1.03	1.01, 1.04	0.001
Sex									
F	—	—		—	—		—	—	
M	0.93	0.69, 1.27	0.67	0.89	0.66, 1.19	0.42	0.91	0.68, 1.21	0.51
`Elixhauser score`	1.07	0.97, 1.17	0.17	1.11	1.01, 1.21	0.034	1.06	0.97, 1.16	0.20
Fluoxetine									
No	—	—							
Yes	0.42	0.20, 0.88	0.022						
Citalopram									
No				—	—				
Yes				1.03	0.49, 2.19	0.94			
Escitalopram									
No							—	—	
Yes							1.11	0.71, 1.74	0.65

¹HR = Hazard Ratio, CI = Confidence Interval

Table S6. Results of Cox Proportional Hazards Regression from 1:2 Matched Cohort (Two Non-SSRI Treated Patients for Each SSRI Treated Patient) and Adjusting for Age, Sex, Elixhauser Comorbid Score, and Treating SSRI Exposures as Time-dependent Variables, Related to Figure 6.

Characteristic	Fluoxetine			Citalopram			Escitalopram		
	HR ¹	95% CI ¹	p-value	HR ¹	95% CI ¹	p-value	HR ¹	95% CI ¹	p-value
Age	1.03	1.00, 1.07	0.046	1.02	0.99, 1.05	0.20	1.03	1.01, 1.06	0.006
Sex									
F	—	—		—	—		—	—	
M	3.24	1.17, 8.94	0.023	1.12	0.59, 2.13	0.73	1.00	0.67, 1.49	>0.99
`Elixhauser score`	1.21	0.89, 1.66	0.22	1.18	0.78, 1.79	0.43	0.98	0.85, 1.13	0.82
Fluoxetine									
No	—	—							
Yes	0.33	0.13, 0.86	0.023						
Citalopram									
No				—	—				
Yes				1.46	0.74, 2.91	0.28			
Escitalopram									
No							—	—	
Yes							1.43	0.91, 2.24	0.12

¹ HR = Hazard Ratio, CI = Confidence Interval